Description
For quote and information, please contact with us via email: info@doronscientific.com
| Product name | Description | Alternative names | INN (International Nonproprietary Name) | Target & species | Storage | Product Size | Species | Concentration | Receptor identification | Price quote contact |
| Alemtuzumab | Alemtuzumab is a humanized monoclonal antibody against CD52,an antigen found on the surface of normal and malignant lymphocytes. | Campath-1H,LDP-03 | Alemtuzumab | CD52[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ruplizumab | Ruplizumab is a humanized monoclonal antibody used as an immunosuppressive drug and is a component of Antova.Ruplizumab is an anti-CD40L monoclonal antibody.The binding of CD40 to its ligand,CD40L is a critical element in T cell activation.In systemic lupus erythematosus,CD40L is over-expressed on T cells, B cells and monocytes. | BG-9588,hu5c8 | Ruplizumab | CD40LG[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Apolizumab | Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.Apolizumab is a humanized monoclonal antibody directed against 1D10,a polymorphic determinant on the HLA-DR beta chain that is expressed on normal and neoplastic B cells.Apolizumab induces complement-mediated cytotoxicity,antibody-dependent cell-mediated cytotoxicity,and apoptosis of 1D10 antigen-positive B cells in vitro. | Hu1D10 | Apolizumab | HLA-DRB[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Bevacizumab | Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab, a humanized monoclonal antibody,specifically binds to all VEGF-A isoforms with high affinity. | 12-IgG1,F(ab)-12 IgG1,Fab-12 IgG1,rhuMAb-VEGF | Bevacizumab | VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Daclizumab | Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences.The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.On 22 April 2008,Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized,for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) 2.Regardless of the withdrawal of Zenapax, Biogen and Abbvie’s Zinbryta (daclizumab),as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis,was approved for use by the FDA in 2016. | BIIB019,DAC HYP | Daclizumab | IL2RA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Eculizumab | Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. | 5G1.1,h5G1.1HuG2/G4 | Eculizumab | C5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-G4-kappa | info@doronscientific.com |
| Efalizumab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a.Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. | hu1124 | Efalizumab | ITGAL/CD11a[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Matuzumab | Matuzumab is a humanized monoclonal antibody used in cancer treatment.It has a high affinity for EGFR, frequently associated with the growth of blood vessels in malignancy,facilitating tumor growth and survival. | EMD-72000,H425,h425 | Matuzumab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Epratuzumab | Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody,LL2 (EPB-2).This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders,such as lupus. | 90Y-DOTA-hLL2,90Y-epratuzumab tetraxetan,AMG-412,90Y-hLL2,hLL2 | Epratuzumab | CD22[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Fontolizumab | Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn’s disease. | HuZAF, | Fontolizumab | IFNG[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Gemtuzumab | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative,a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp.calichensis.Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label.The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML).By binding to the CD33 antigen on tumors,the cytotoxic agent blocks the growth of cancerous cells and causes cell death. | CDP-771,CMA-676 (ADC),WAY-CMA-676,gemtuzumab ozogamicin,hP67.6 (naked),hP67.6-calicheamicin (ADC) | Gemtuzumab | CD33[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Cantuzumab Mertansine | SB408075,huC242-DM1 | Cantuzumab Mertansine | CA242[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Lintuzumab | Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia). | 225Ac-lintuzumab,HuM195,SGN-33,SMART M195 | Lintuzumab | CD33[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lorvotuzumab Mertansine | Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC,Leukemia, Ovarian Cancer,Multiple Myeloma,and Merkel Cell Carcinoma,among others. | BB-10901,IMGN901,huN901-DM1 | Lorvotuzumab Mertansine | NCAM1/CD56[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Labetuzumab | Labetuzumab is a humanized monoclonal antibody to carcinoembryonic antigen that inhibits tumor growth. It is used in radioimmunotherapy. | hMN14 | Labetuzumab | CEACAM5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG-nd | info@doronscientific.com |
| Amatuximab | Amatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer,Ovarian Neoplasms,Pancreatic Cancer,and Mesothelioma,Malignant,among others. | MORAb-009 | Amatuximab | MSLN[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Naptumomab Estafenatox | Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma. | ABR-217620,ANYARA,TTS CD3 | Naptumomab Estafenatox | TPBG[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab-G1-kappa | info@doronscientific.com |
| Siplizumab | Siplizumab has been shown to cause depletion of T-cells.It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits,such as certain autoimmune diseases and T-cell cancers.In addition, preclinical studies have also suggested that siplizumab,by binding to the CD2 receptor,may selectively produce cell death and reduce cancerous cells. | MEDI-507 | Siplizumab | CD2/LFA-2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Motavizumab | Motavizumab is a second generation,ultra-potent, affinity-matured,humanized mAb derived from palivizumab that reduces replication of Respiratory Syncytial Virus (RSV),a pathogen which causes lower respiratory tract disease. | MEDI-524 | Motavizumab | RSV[Respiratory syncytial virus] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Natalizumab | Natalizumab is a recombinant, humanized monoclonal antibody,binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1).Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn’s disease.Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses. | AN 100226,BG00002 | Natalizumab | ITGA4/CD49d[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Nimotuzumab | Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR). | Theraloc,hR3 | Nimotuzumab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Omalizumab | Omalizumab is a recombinant,humanized,monoclonal antibody against human immunoglobulin E (IgE). | IGE25,olizumab,pSVIE26,rhuMab-E25 | Omalizumab | IGHE[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Cedelizumab | ORTHOCLONE OKT4 A | Cedelizumab | CD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Palivizumab | Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology,directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV).Synagis is a composite of human (95%) and murine (5%) antibody sequences.The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2).The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0).Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each),contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF). | MEDI-493 | Palivizumab | RSV[Respiratory syncytial virus] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Pertuzumab | Pertuzumab (anti-HER2),a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors,impairs the ability of HER2 to bind to other members of the HER family. | OMNITARG,rhuMAB 2C4 | Pertuzumab | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Pexelizumab | Pexelizumab is a humanized monoclonal antibody used as an immunosuppressive drug.It is being investigated by Alexion Pharmaceuticals. | 5G1.1-SC | Pexelizumab | C5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | scFv-nd-nd | info@doronscientific.com |
| Sevirumab | EV2 7,MSL 109,SDZ MSL 109 | Sevirumab | HCMV[Human herpesvirus 6] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Ranibizumab | Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A. | Fab-12 variant Y0317,RhuFab | Ranibizumab | VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab-G1-kappa | info@doronscientific.com |
| Felvizumab | SB 209763 | Felvizumab | RSV[Respiratory syncytial virus] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Mepolizumab | Mepolizumab is a humanized IL-5 antagonist monoclonal antibody produced by recombinant DNA technology in Chinese hamster ovary cells.It has a molecular weight of approximately 149 kDa.It was approved by the FDA in November,2015 for the treatment of asthma under the brand name Nucala (marketed by GlaxoSmithKline).Mepolizumab has been investigated in the treatment of severe nasal polyposis,among numerous other conditions.Mepolizumab is an interleukin-5 antagonist (IgG1 kappa).IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation,and survival of eosinophils.Mepolizumab binds to IL-5 with a dissociation constant of 100 pM,inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface.Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells,eosinophils, neutrophils,macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in inflammation.Mepolizumab,by inhibiting IL-5 signaling, reduces the production and survival of eosinophils;however,the mechanism of mepolizumab action in asthma has not been definitively established. | SB-240563 | Mepolizumab | IL5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Pascolizumab | Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Pascolizumab is a humanized anti-IL-4 monoclonal antibody that can inhibit upstream and downstream events associated with asthma, including (T(H)2) cell activation and immunoglobulin E production. | SB-240683 | Pascolizumab | IL4[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Foravirumab | CR4098 | Foravirumab | RV[Rabies virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Rafivirumab | CR57 | Rafivirumab | RV[Rabies virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Visilizumab | Visilizumab has been investigated for the treatment of Ulcerative Colitis. | HuM291 | Visilizumab | CD3E[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-nd | info@doronscientific.com |
| Blinatumomab | Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).Blinatumomab is manufactured by Amgen Inc.and marketed under the brand Blincyto™.Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program,which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients. | AMG103,BITE MT-103,MEDI-538,MT103,bscCD19xCD3 | Blinatumomab | CD19/CD3E[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | (scFv-kappa-heavy)-(scFv-heavy-kappa) | info@doronscientific.com |
| Gevokizumab | Gevokizumab has been used in trials studying the treatment of Acne Vulgaris,Osteoarthritis, Behcet’s Uveitis,Pyoderma Gangrenosum, and Behcet’s Disease Uveitis,among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states.It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors. | XOMA 052 | Gevokizumab | IL1B[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Tadocizumab | C4G1,YM-337 | Tadocizumab | ITGA2B_ITGB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab-G1-kappa | info@doronscientific.com | |
| Yfc51.1Mab | YFC51.1 | Yfc51.1Mab | ITGB2/CD18[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Yth12.5 | YTH12.5 | Yth12.5 | CD3E[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Rivabazumab Pegol | KB001-A | Rivabazumab Pegol | PcrV type III secretion system PcrV protein[Pseudomonas aeruginosa,Gram negative bacteria] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab’-G1-kappa | info@doronscientific.com | |
| 14F7 | 14F7 | 14F7 | ganglioside N-glycolyl GM3[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| 4F2Mab | 14G2a,4F2 | 4F2Mab | ganglioside GD2/ SFRP1/SLC3A2[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus,Humanized | 1mg/ml | IgG2a-nd; IgG1-nd | info@doronscientific.com | |
| Huj591-Gsmab | 177 Lu-J591,HuJ591-GS | Huj591-Gsmab | FOLH1/PSMA[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | info@doronscientific.com | ||
| Abagovomab | ACA125,MEN-2234 | Abagovomab | idiotope of anti- Mus musculus monoclonal antibodyOC126[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Gavilimomab | ABX-CBL | Gavilimomab | BSG/CD147[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgM-nd | info@doronscientific.com | |
| Arcitumomab | CEA-Scan,IMMU-4 | Arcitumomab | CEACAM5/CD66e[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab’-G1-nd | info@doronscientific.com | |
| Capromab | 7E11-C5.3 radiolabelled,Indium In1111 ProstaScint-,capromab pendetide | Capromab | FOLH2[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Campath-9H | CYT-356-Y-90,Campath-9H | Campath-9H | CD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Edobacomab | E5,XMMEN-0E5 | Edobacomab | Endotoxin[Gram negative bacteria] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgM-nd | info@doronscientific.com | |
| Edrecolomab | 17-1A | Edrecolomab | EPCAM[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2a-kappa | info@doronscientific.com | |
| Enlimomab | BI-RR-1,BIRR-1 | Enlimomab | ICAM1[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2a-nd | info@doronscientific.com | |
| Hnk20Mab | HNK20 | Hnk20Mab | RSV glycoprotein F[Respiratory syncytial virus] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgA-nd | info@doronscientific.com | |
| Ibritumomab Tiuxetan | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen,which is found on the surface of normal and malignant B lymphocytes.Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.The Fab segment of the antibody targets the CD20 epitope on B-cells,allowing the radioactive yttrium to destroy the cell via production of beta particles. | In-111 Zevalin,Y-90 Zevalin | Ibritumomab Tiuxetan | MS4A1[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Igovomab | Indimacis 125,OC125 chelator DTPA | Igovomab | MUC16[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | F(ab’)2-G1-nd | info@doronscientific.com | |
| Imciromab | R1D10 pentetate | Imciromab | Myosin/Cardiac[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab-G2a-kappa | info@doronscientific.com | |
| Immurait-Ll2Mab | 131I-IMMU-LL2, ImmuRAIT-LL2 | Immurait-Ll2Mab | CD22[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2a-kappa | info@doronscientific.com | |
| Inolimomab | Inolimomab is under investigation in clinical trial NCT04289103 (Evaluation of Efficacy and Safety of Leukotac (Inolimomab) in Pediatric Patients With Sr-agvhd). | Inolimomab | IL2RA[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Afelimomab | MAK-195F | Afelimomab | TNFSF2/TNF-alpha/TNFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | F(ab’)2-G3-kappa | info@doronscientific.com | |
| T10B9.1A-31 | MEDI-500,T10B9,T10B9.1A-31 | T10B9.1A-31 | T cell receptor[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgM-kappa | info@doronscientific.com | |
| Mitumomab | Mitumomab, an anti-BEC-2 monoclonal antibody derived from mice,was previously studied to treat small cell lung carcinoma in combination with BCG vaccination. | BEC2 | Mitumomab | Ganglioside GD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2b-kappa | info@doronscientific.com |
| Biciromab | Indium (111In) biciromab,T2G1 | Biciromab | Fibrin II beta chain,fibrin[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab’-G1-kappa | info@doronscientific.com | |
| Muromonab-Cd3 | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens.More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method.Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain.It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis,antibody mediated cytotoxicity and complement-dependent cytotoxicity. | OKT3 | Muromonab-Cd3 | CD3E[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2a-kappa | info@doronscientific.com |
| Technetium (99Mtc) Nofetumomab Merpentan | Technetium Tc-99m nofetumomab merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10.1 The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues.Label Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992. It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.The mechanism of action in Tc-99m nm is ruled by the presence of nofetumomab, which can recognize the pancarcinoma antigen EpCAM and/or CD20/MS4A1,2 and merpentan,that acts as a linker for the binding of technetium. | Technetium (99Mtc) Nofetumomab Merpentan | IL3RA/CD123[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Odulimomab | afolimomab,anti-LFA1 | Odulimomab | ITGAL/CD11a[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | F(ab’)2-G1-nd | info@doronscientific.com | |
| Milatuzumab | Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others. | CD74-DOX (ADC),MEDI-115,hLL1,hLL1-DOX (ADC) | Milatuzumab | CD74[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Oregovomab | Oregovomab is a murine monoclonal antibody that attaches to the tumor-associated antigen CA125. | MAB-B43.13,oregovamab | Oregovomab | MUC16/CA125[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Cc49 | CC49 | Cc49 | TAG-72[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | info@doronscientific.com | ||
| Satumomab | Indium (111In) satumomab pendetide,OncoScint CR/OV,OncoScint CR103 | Satumomab | TAG-72[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Sulesomab | Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes. | IMMU-MN3,Technetium (99mTc) sulesomab,LeukoScan | Sulesomab | NCA-90[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab’-G1-nd | info@doronscientific.com |
| Tecnemab | 225.28S,Tecnemab-K-1,3-4D10,4D5-8 and UCHT1,BsF(ab’)2 v1,F(ab’)2 trastusumab/humanized UCHT1-v1,F(ab＊)2 4D5-8/UCHT1-v1 | Tecnemab | CSPG4/HMW-MAA/CD3E/ERBB2[Homo sapiens],toxin[Clostridium perfringens] | store at -80°C | 100ug and 1mg | Mus musculus,Humanized | 1mg/ml | F(ab’)2, Fab / Fab2 mix, IgG1-nd, F(ab’)2-G1-kappa | info@doronscientific.com | |
| Tositumomab | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues).It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).Binds to the CD20 antigen which is found on mature B lymphocytes.The antibody binding appears to induce apoptosis, complement-dependent cytotoxicity and cell death through ionizing radiation. | Tositumomab | MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2a-lambda | info@doronscientific.com | |
| Iodine (131I) Derlotuximab Biotin | (131)I-chTNT-1/B,I-131 ch-TNT-1/B,131I-chTNT(Tumor Necrosis Therapy)-1/B | Iodine (131I) Derlotuximab Biotin | DNA/histone(H1) complex[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| cT84.66 | 90Y-cT84.66 | cT84.66 | CEACAM5/CD66e[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | info@doronscientific.com | ||
| Abciximab | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3.Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen,von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.Abciximab binds to the intact platelet GPIIb/IIIa receptor,which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation.This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa.By binding to the vitronectin receptor (also known as the αvβ3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion.Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion. | c7E3 | Abciximab | ITGA2B_ITGB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | Fab-G1-kappa | info@doronscientific.com |
| Alg-991 | ALG-991 | Alg-991 | Urushiol[Toxicodendron] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgM-nd | info@doronscientific.com | |
| Basiliximab | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent,specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes.It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes and mouse heavy and light chain variable region genes encoding the RFT5 antibody that binds selectively to the IL-2R alpha.Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor.This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney. | CHI621 | Basiliximab | IL2RA/CD25[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Bavituximab | Bavituximab is a chimeric Anti-PS monoclonal antibody analog which is used to potentially treat cancers and viral infections. It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.Bavituximab Anti-Cancer is a monoclonal antibody that binds to a basic component of the cell structure called a phospholipid that is exposed only on the surface of tumor blood vessel cells or on cells infected with certain viruses. Bavituximab binding to the tumor blood vessel cells alerts the body’s immune system to attack the tumor and its blood supply. This has been shown to inhibit tumor growth and development. Because in healthy cells the phospholipids are concealed inside the cell, the bavituximab does not bind to them. This targets the bavituximab to the malignant cells and potentially minimizes unwanted side effects. | Tarvacin ch3G4 | Bavituximab | Phosphatidylserine[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| cBR96 | cBR96,huAnti-B4,humanized B1-8,humanized D1.3,humanized DX48,humanized K20,humanized-HCMV16,humanized-HCMV37, | cBR96 | Lewis Y[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa, | info@doronscientific.com | |
| Cetuximab | Cetuximab is an epidermal growth factor receptor binding FAB.Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company.In the United States,a regimen of cetuximab costs approximately $30,790 for an eight-week course.Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers.Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha,thereby reducing their effects on cell growth and metastatic spread. | Fab C225,IMC-225 | Cetuximab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Clenoliximab | Clenoliximab is a chimeric monoclonal antibody from Macaca irus against CD4 which acts as an immunomodulator.It has investigated for the treatment of rheumatoid arthritis. | CE9，4PE,IDEC-151 | Clenoliximab | CD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG4-lambda | info@doronscientific.com |
| 12D10-Fab | 12D10 Fab,12D10-Fab | 12D10-Fab | F7[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | Fab-nd-nd | info@doronscientific.com | |
| Galiximab | Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. | IDEC-114 | Galiximab | CD80 (B7-1,CD28LG2)[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| ICM3 | IC14, ICM3 | ICM3 | CD14 /ICAM3[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | info@doronscientific.com | ||
| Infliximab | Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn’s disease and rheumatoid arthritis.Infliximab is a IgG1κ monoclonal antibody that binds to soluble and transmembrane forms of TNF-α with high affinity to disrupt the pro-inflammatory cascade signalling.Binding of the antibody to TNF-α prevents TNF-α from interacting with its receptors.Infliximab does not neutralize TNF-β (lymphotoxin-α),a related cytokine that utilizes the same receptors as TNF-α Label.Blocked actions of TNF-α further leads to downregulation of local and systemic pro-inflammatory cytokines (i.e. IL-1, IL-6),reduction of lymphocyte and leukocyte migration to sites of inflammation, induction of apoptosis of TNF-producing cells (i.e. activated monocytes and T lymphocytes),increased levels of nuclear factor-κB inhibitor, and reduction of reduction of endothelial adhesion molecules and acute phase proteins 3. Its inhibitory actions on TNF-α was demonstrated in human fibroblasts,endothelial cells, neutrophils, B and Tlymphocytes and epithelial cells Label.Infliximab also atteunates the production of tissue degrading enzymes synthesized by synoviocytes and/or chondrocytes. According to a transgenic mice study that developed polyarthritis due to consitutive levels of human TNF-α,infliximab decreased synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal Label. | TA-650,cA2 | Infliximab | TNF-alpha[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Keliximab | IDEC CE9.1/SB-210396 | Keliximab | CD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Lumiliximab | Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody,for the potential treatment of allergic conditions.Lumiliximab was developed by IDEC Pharmaceuticals,which was acquired by Biogen.Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23,a protein expressed on virtually all chronic lymphocytic leukemia (CLL) cells.CD23, also known as Fc epsilon RII,or FcεRII,is the “low affinity” receptor for IgE, an antibody isotype involved in allergy and resistance to parasites and is important in regulation of IgE levels. Unlike many of the antibody receptors, CD23 is a C-type lectin. It is found on mature B cells,activated macrophages, eosinophils, follicular dendritic cells and platelets. | IDEC-152,P5E8 | Lumiliximab | FCER2[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Oncolym | Iodine 131-ILym-1,Lym-1,Oncolym | Oncolym | HLA-DR10[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2a-nd | info@doronscientific.com | |
| Priliximab | cm-MT412 | Priliximab | CD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Rituximab | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin’s Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label. | IDEC-C2B8 | Rituximab | MS4A1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Briakinumab | Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.Briakinumab targets and neutralizes interleukin-12 and interleukin-23. | ABT-874 | Briakinumab | IL12B[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| ABX-IL8 | ABX-IL8 | ABX-IL8 | IL8[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-nd | info@doronscientific.com | |
| Adecatumumab | Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.Adecatumumab (MT201) is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has been shown to promote the proliferation, migration and invasiveness of breast cancer cells. Moreover, expression of EpCAM is associated with decreased survival in a number of cancer indications, including breast, gall bladder, bile duct, ovarian and ampullary pancreatic cancer. EpCAM has recently been shown to be expressed on cancer stem cells from breast, prostate, colon and pancreatic cancer. Clinical studies have shown a favorable safety profile and that clinical activity depends on the EpCAM target expression. | MT201 | Adecatumumab | EPCAM[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Adalimumab | Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor 2, 3. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA 1. This drug is frequently known as Humira. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses 1. A new biosimilar to adalimumab, named adalimumab-adaz, was approved by the FDA on October 31, 2018. This biosimilar is known as Hyrimoz, and is a trademark of Novartis AG 9. | D2E7 | Adalimumab | TNFSF2/TNF-alpha/TNFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Mk-4721 | AGS-PSCA,MK-4721 | Mk-4721 | PSCA[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Al-901 | AL-901 | Al-901 | IGHE[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | info@doronscientific.com | ||
| Ganitumab | Ganitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others. | AMG 479 | Ganitumab | IGF1R/CD221[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tuvirumab | anti-hepatitis B | Tuvirumab | HBV[Hepatitis B virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Bertilimumab | CAT-213,iCo-008 | Bertilimumab | CCL11[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Tralokinumab | Tralokinumab is under investigation for the treatment of Alopecia Areata. Tralokinumab has been investigated for the treatment of Asthma. | CAT-354 | Tralokinumab | IL13[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-lambda | info@doronscientific.com |
| Ustekinumab | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses.2 It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice.2 It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways.Interleukin (IL)-12 and IL-23 are heterodimeric cytokines that evoke immune and inflammatory responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.The role of IL-12 and IL-23 were implicated in a variety of chronic inflammatory conditions, such as psoriasis and inflammatory bowel diseases. They modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets,2 as CD4+ T cells can differentiate into T-helper (Th) effector lineages based on the environment. Th cells can further activate the downstream pro-inflammatory mediators and transcription factors such as TNFα and IFNγ that drive innate and adaptive immunity. | CNTO 1275,TT-20 | Ustekinumab | IL12B[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Efungumab | HSP90mab,Mycograb | Efungumab | HSP91 homolog[Candida albicans] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | scFv-heavy-kappa | info@doronscientific.com | |
| Fresolimumab | Fresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis. | GC-1008 | Fresolimumab | TGFB/TGF beta[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Golimumab | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.As a human monoclonal antibody, golimumab binds and inhibits soluble and transmembrane human TNFα. Inhibition of TNFα prevents it binding to its receptors, which prevents both leukocyte infiltration through prevention of cell adhesion proteins such as E-selectin, ICAM-1 and VCAM-1, and pro-inflammatory cytokine secretion such as IL-6, IL-8, G-CSF and GM-CSF in vitro. Consequently, in patients with chronic inflammatory conditions, decreases in ICAM-1 and IL-6 as well as C-reactive protein (CRP), matrix metalloproteinase 3 (MMP-3), and vascular endothelial growth factor (VEGF) were observed. | CNTO 148 | Golimumab | TNFA/TNF alpha[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lucatumumab | HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies. | CHIR-12,12,HCD122 | Lucatumumab | CD40[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Humax-Il15 | AMG 714,HuMax-IL15 | Humax-Il15 | IL15[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| IMC-1C11 | IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.IMC-1C11 is a chimerized antibody that targets the KDR receptor (also referred to as VEGFr) on vascular endothelial cells by inhibiting binding of the essential ligand, vascular endothelial growth factor (VEGF), to its receptor. KDR is a key receptor associated with tumor angiogenesis. As solid tumors cannot grow efficiently without new blood supply, use of IMC-1C11 results in the inhibition of tumor growth and death of tumor cells by apoptosis. | IMC-1C11 | IMC-1C11 | VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | info@doronscientific.com | |
| Ipilimumab | Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells.3 CTLA-4 and CD28 are both presented on the surface of T-cells.3 Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors. | BMS-734016,MDX-010,MDX-CTLA-4 | Ipilimumab | CTLA4/CD152[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| J695 | J695,LDP-01,MLNM2201 | J695 | IL12A/CD18[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens,Humanized | 1mg/ml | IgG-nd | info@doronscientific.com | |
| Lerdelimumab | CAT-152,Trabio | Lerdelimumab | TGFB2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-nd | info@doronscientific.com | |
| Lexatumumab | Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).Lexatumumab agonizes the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAIL-R2), triggering the extrinsic apoptotic pathway. | HGS-ETR2 | Lexatumumab | TNFRSF10B/CD262[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Mapatumumab | HGS-ETR1,TRM-1 | Mapatumumab | TNFRSF10A/CD261[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| HuCC49 | H22, MDX-33,H52, Huh52,HCC49,HuCC49 | HuCC49 | FCGR1/ITGB2/TAG-72[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Metelimumab | CAT-192 | Metelimumab | TGFB1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| MOR101 | MOR101 | MOR101 | ICAM1/CD54[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | Fab-nd-nd | info@doronscientific.com | |
| MOR102 | MOR102 | MOR102 | ICAM1/CD54[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | Fab-G4-nd | info@doronscientific.com | |
| Otilimab | Investigated for the treatment of osteoarthritis and rheumatoid arthritis (RA). | MOR-04357,3196165,GSK3196165,MOR103 | Otilimab | CSF2/GM-CSF[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| MOR202 | MOR202 | MOR202 | CD38[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| MORAb-028 | MORAb-028, MaE11 | MORAb-028 | Ganglioside GD2/IGHE[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens,Humanized | 1mg/ml | IgM-nd;IgG1-nd | info@doronscientific.com | |
| Stamulumab | MYO-029 | Stamulumab | MSTN/GDF-8[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Nebacumab | HA-1A,centoxin,septomonab | Nebacumab | Endotoxin[Gram negative bacteria] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgM-kappa | info@doronscientific.com | |
| Ofatumumab | Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. | HuMax-CD20 | Ofatumumab | MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| OST 577 | OST 577 | OST 577 | HBV[Hepatitis B virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | info@doronscientific.com | ||
| Panitumumab | Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.Ruplizumab is an anti-CD40L monoclonal antibody. The binding of CD40 to its ligand, CD40L, is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells, and monocytes. | ABX-EGF,E7.6.3 | Panitumumab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Regavirumab | C23,MCA C23,TI-23 | Regavirumab | HCMV[Human herpesvirus 6] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Moxetumomab Pasudotox | CD22 is a lineage-restricted B-cell antigen that is expressed solely in on B-chronic lymphocytic leukemia, hairy cell leukemia, acute lymphocytic leukemiathe and Burkitt’s lymphoma. The predecessor of Moxetumab pasudotox (MxP), named BL22, was first created based on the antibody RFB4 which specifically binds to CD22. This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the Pseudomonas exotoxin A (PE38) which does not have the cell-binding portion. | CAT-8015,GCR-8015,HA22,moxetumomab pasudotox -tdfk | Moxetumomab Pasudotox | CD22[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fv-disulfide stabilized | info@doronscientific.com |
| Votumumab | Technetium (99mTc) votumumab | Votumumab | carcinoma associated antigen CTAA16[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG3-kappa | info@doronscientific.com | |
| Zalutumumab | Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer. | HuMax-EGFr | Zalutumumab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Zanolimumab | HuMax-CD4 | Zanolimumab | CD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| CMB-401 | CMB-401,hCTMO1-calicheamicin;CDP 671 | CMB-401 | MUC1/CD227[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| CDP571 | B3 (dsFv) -PE38,LMB-9 BAY 103356,BAY W 3356,CDP571 | CDP571 | TNFSF2/TNF alpha/TNFA[Homo sapiens] | store at -80°C | 100ug and 1mg | 1mg/ml | IgG4-kappa | info@doronscientific.com | ||
| Dorlimomab Aritox | 4197X-RA,MDX-RA (ricin A chain) immunotoxin | Dorlimomab Aritox | (ricin A chain) immunotoxin | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | F(ab’)2-nd-nd | info@doronscientific.com | |
| Catumaxomab | Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites 3. Its market authorization was withdrawn in the EU in June 2017 at the manufacturer’s request due to the company’s insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition Label. It is currently available under the brand name Removab. | Musmus G2a kappa,anti-EPCAM (Ho-3/TP-A-01)/Rat sp.G2b lambda,anti-CD3E (26/II/6-1.2),TPBs01 | Catumaxomab | CD3E/EpCAM[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus,Rattus sp,Hybrid | 1mg/ml | IgG2a-kappa/G2b-lambda | info@doronscientific.com |
| Ertumaxomab | Musmus G2a kappa,anti-ERBB2 (250A/TP-A-02)/Rat sp.G2b lambda,anti-CD3E (26/II/6-1.2),TPBs03 | Ertumaxomab | CD3E/ERBB2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus,Rattus sp,Hybrid | 1mg/ml | IgG2a-kappa/G2b-lambda | info@doronscientific.com | |
| Gantenerumab | Gantenerumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial. | R1450 | Gantenerumab | APP /Abeta42/Abeta40[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Conatumumab | Conatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others. | AMG 655,TRAIL-R2mAb,XG1-048 v w | Conatumumab | TNFRSF10B/CD262[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Racotumomab | Racotumomab has been used in trials studying the treatment of Glioma, Wilm’s Tumor, Neuroblastoma, Retinoblastoma, and Ewing’s Sarcoma. | Racotumomab | Idiotope of anti-(N-glycolylneuraminic acid (NeuGc,NGNA) -gangliosides GM3) Mus musculus IgM-kappa monoclonal antibody P3[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tenatumomab | ST2146 | Tenatumomab | TNC/HXB[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2b-nd | info@doronscientific.com | |
| Ocrelizumab | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets the B lymphocytes that express the CD20 antigen. As a humanized molecule, ocrelizumab is expected to be less immunogenic with repeated infusions which improves the benefit-to-risk profile for patients with relapsing or progressive forms of MS. | 2H7 | Ocrelizumab | MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Camidanlumab | ADCT-301(unconjugated),HuMax-TAC-ADC | Camidanlumab | IL2RA/CD25[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Yttrium (90Y) Clivatuzumab Tetraxetan | IMMU-107 | Yttrium (90Y) Clivatuzumab Tetraxetan | MUC1/CD227[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tanezumab | Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic. | PF-04383119,RN624 | Tanezumab | IGHE[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Anrukinzumab | Anrukinzumab has been used in trials studying the diagnostic of Asthma. | IMA-638 | Anrukinzumab | IL13[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Dacetuzumab | Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells. | SGN-40,huS2C | Dacetuzumab | CD40[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Alacizumab Pegol | CDP791,g165 DFM-PEG | Alacizumab Pegol | KDR/VEGFR2/CD309[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | di-Fab’ | info@doronscientific.com | |
| Tigatuzumab | Tigatuzumab is under investigation in clinical trial NCT00991796,CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC). | CS-1008,TRA-8 | Tigatuzumab | TNFRSF10B/CD262[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Otelixizumab | Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity. Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis. | ChAglyCD,TRX4 | Otelixizumab | CD3E[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Citatuzumab Bogatox | VB6-845 | Citatuzumab Bogatox | EPCAM/CD326[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab-G1-kappa | info@doronscientific.com | |
| Oportuzumab Monatox | VB4-845 is studied in the treatment of certain types of head and neck cancer. VB4-845 is made by linking a monoclonal antibody fragment to a toxic protein that may kill cancer cells. VB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin and a truncated portion of Pseudomonas exotoxin A. | VB4-845 | Oportuzumab Monatox | EPCAM/CD326[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | scFv-kappa-heavy | info@doronscientific.com |
| Obinutuzumab | Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Leukoencephalopathy (PML). | GA101,RG7159,RO5072759,afutuzumab | Obinutuzumab | MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Etaracizumab | Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer. | MEDI-522,hLM60 | Etaracizumab | ITGAV_ITGB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Ibalizumab | Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies 8,5. | Hu5A8,TMB-355,TNX-355 | Ibalizumab | CD4 D3 domain[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Certolizumab Pegol | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).1 It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. | CDP870,PHA-738144 | Certolizumab Pegol | TNFSF2/TNF-alpha/TNFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab’-G1-kappa | info@doronscientific.com |
| Panobacumab | Panobacumab is under investigation in clinical trial NCT00851435 (Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa). | Aerumab 11,KBPA101 | Panobacumab | Serotype IATS O12[Pseudomonas aeruginosa, Gram negative bacteria] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgM-kappa | info@doronscientific.com |
| Canakinumab | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients. | ACZ885 | Canakinumab | IL1B[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tremelimumab | Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies. | CP-675,CP-675,206,CP-675206 clone 11.2.1 | Tremelimumab | CTLA4/CD152[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Denosumab | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010. | AMG162 | Denosumab | TNFSF11/CD254[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Iratumumab | Immunoglobulin G1, anti-(human CD30 (antigen)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer. Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas. | MDX-060 | Iratumumab | TNFRSF8/CD30[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Sontuzumab | AS1402,huHMFG-1 | Sontuzumab | MUC1/CD227[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Bapineuzumab | Bapineuzumab has been investigated for the treatment of Alzheimer’s Disease. | AAB-001 | Bapineuzumab | APP Abeta[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Pagibaximab | BSYX-A110,PMAB | Pagibaximab | Staphylococcus epidermidis lipoteichoic acid[Staphylococcus epidermidis] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tucotuzumab Celmoleukin | Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment). | EMD 273066,KSA-Interleukin-2,huKS-IL2,huKS1/4-IL-2 | Tucotuzumab Celmoleukin | EPCAM/CD326[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Yttrium (90Y) Tacatuzumab Tetraxetan | hAFP-31 | Yttrium (90Y) Tacatuzumab Tetraxetan | AFP[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Volociximab | Volociximab | ITGA5/CD49e[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG4-nd | info@doronscientific.com | ||
| Besilesomab | Besilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis Label. Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the Netherlands, and the United Kingdom 3. | BW250/183 | Besilesomab | CEACAM8/CD66b[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Inotuzumab Ozogamicin | Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent 4. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of fully remission with no evidence of disease in comparison to patients receiving alternative chemotherapy 5. | CMC-544 | Inotuzumab Ozogamicin | CD22[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Raxibacumab | Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012. | Raxibacumab | Anthrax protective antigen [Bacillus anthracis] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Tefibazumab | Aurexis | Tefibazumab | Fibrin-binding surface epitope clumping factor A[Staphylococcus aureus] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Exbivirumab | 19.79.5,HepeX-B-(combination of exbivirumab and libivirumab) | Exbivirumab | HBV/HBsAg[Hepatitis B virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Libivirumab | 17.1.41,HepeX-B-(combination of exbivirumab and libivirumab) | Libivirumab | HBV/HBsAg[Hepatitis B virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Urtoxazumab | HuVTm1.1,TMA-15 | Urtoxazumab | Stx-2/SLT-II[Escherichia coli] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Belimumab | Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain. | LymphoStat-B,hBlySmAb-1.1 | Belimumab | TNFSF13B/CD257[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Elsilimomab | B-E8 | Elsilimomab | IL6[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Epitumomab Cituxetan | Epitumomab Cituxetan | MUC1/CD227 [Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | ||
| Pritumumab | CLN G11 | Pritumumab | VIM [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Talizumab | C21/AL-90,HU-901,Hu901,TNX-901 | Talizumab | CD3E/GPRC5D[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG4-kappa-lambda | info@doronscientific.com | |
| Aselizumab | HuDreg-55 | Aselizumab | SELL/CD62L [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-nd | info@doronscientific.com | |
| Ecromeximab | Ecromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma. | KM871,KW-2871 | Ecromeximab | ganglioside GD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Teneliximab | chi220 | Teneliximab | CD40/TNFRSF5[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Vapaliximab | 2D10 | Vapaliximab | AOC3/VAP-1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Reslizumab | Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively. | CDP-835,JES1-39D10,SCH55700 | Reslizumab | IL5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-nd | info@doronscientific.com |
| Erlizumab | rhuMAb | Erlizumab | ITGB2/CD18 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Lemalesomab | 78NCA-90, IMMU-MN3 | Lemalesomab | NCA-90 [Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Taplitumomab Paptox | Taplitumomab Paptox | DPEP3 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | ||
| Bivatuzumab | Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. | BIWA4 | Bivatuzumab | CD44 /CD44V[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Sibrotuzumab | Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer. | BIBH1 | Sibrotuzumab | FAP[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Technetium (99Mtc) Pintumomab | 170 | Technetium (99Mtc) Pintumomab | DPEP3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Anatumomab Mafenatox | ABR-214936,pMB125 | Anatumomab Mafenatox | TAG-72[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab-G1-kappa | info@doronscientific.com | |
| Cixutumumab | Cixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types. |
IMC-A12,LY3012217 | Cixutumumab | IGF1R/CD221[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Elotuzumab | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. | BMS-901608,PDL063;HuLuc63 | Elotuzumab | SLAMF7/CD319[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Farletuzumab | Farletuzumab (MORAb-003) is a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer. | M3,MORAb-003 | Farletuzumab | FOLR1 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Figitumumab | Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others. | CP-751871 | Figitumumab | IGF1R/CD221[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Necitumumab | Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). | 11F8,IMC-11F8,LY3012211 | Necitumumab | EGFR/ERBB1 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ramucirumab | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy. | 1121B,IMC-1121B,LY3009806 | Ramucirumab | KDR/CD309[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Robatumumab | Robatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing’s, and Peripheral Neuroectodermal Tumor. | 19D12,SCH 717454 | Robatumumab | IGF1R/CD221 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Siltuximab | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. | CLLB8,CNTO 328 | Siltuximab | IL6[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Solanezumab | Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial. | LY2062430 | Solanezumab | APP Abeta,soluble monomer[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Vedolizumab | Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn’s disease. | LDP-02,LDP02,MLN-02,MLN0002,MLN02 | Vedolizumab | ITGA4_ITGB7[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Daratumumab | Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. | HuMax-CD38 | Daratumumab | CD38[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Rilotumumab | Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others. | Rilotumumab | HGF[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Epitumomab | B1R1 | Epitumomab | MS4A1[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2a-nd | info@doronscientific.com | |
| Rovelizumab | Hu23F2G | Rovelizumab | ITGAL/CD11a/ITGB2/CD18[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-nd | info@doronscientific.com | |
| Faralimomab | 64G12 | Faralimomab | IFNA1[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Bectumomab | Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it’s used to treat non-Hodgkin’s lymphoma. It has a radioisotope, technetium (99m TC) which it’s added. | 99mTc-IMMU-LL2 | Bectumomab | CD22[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab’-G2a-kappa | info@doronscientific.com |
| Nerelimomab | BAYX1351 | Nerelimomab | TNFSF2/TNF-alpha/TNFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Atorolimumab | P3x22914G4 | Atorolimumab | RHD/CD240D[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG3-kappa | info@doronscientific.com | |
| Minretumomab | Mab CC-49 | Minretumomab | TAG-72[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Vepalimomab | 1B2 | Vepalimomab | AOC3/VAP1[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgM-nd | info@doronscientific.com | |
| Morolimumab | Morolimumab | RHD/CD240D[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com | ||
| Altumomab | ZCE025 | Altumomab | CEACAM5/CD66e[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Detumomab | SPECIFID(panel of 15 anti-idiotype antibodies) | Detumomab | B-cell lymphomas [Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1 | info@doronscientific.com | |
| Zolimomab Aritox | H65-ricin A chain immunotoxin,H65-RTA | Zolimomab Aritox | CD5[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-nd | info@doronscientific.com | |
| Nacolomab Tafenatox | r-c242Fab-SEA | Nacolomab Tafenatox | MUC1 sialylated CA242[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab-G1-kappa | info@doronscientific.com | |
| Enlimomab Pegol | Enlimomab Pegol | ICAM1/CD54[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab’-G2a-nd | info@doronscientific.com | ||
| Maslimomab | Maslimomab | T cell receptor[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2b-nd | info@doronscientific.com | ||
| Telimomab Aritox | T101-ricin A chain immunotoxin,T101-RTA | Telimomab Aritox | CD5 [Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab-nd-nd | info@doronscientific.com | |
| Intetumumab | Intetumumab has been used in trials studying the treatment of Melanoma. | CNTO 095 | Intetumumab | ITGAV_ITGB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Sifalimumab | Sifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders, and may be associated with disease activity. Sifalimumab may suppress the abnormal immune activity associated with lupus by binding to multiple interferon-alpha subtypes seen in the serum of lupus patients. | MDX-1103,MEDI-545 | Sifalimumab | IFNA1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Fezakinumab | Fezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis. | ILV-094 | Fezakinumab | IL22[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Brentuximab Vedotin | Brentuximab vedotin是靶向CD30的新型抗体偶联药物（ADC），MMAE（一种微管抑制剂）通过共价键与抗体相连。非临床数据表明，Brentuximab vedotin的抗肿瘤活性是通过ADC与CD30表达细胞形成的复合物内化及蛋白水解切割，释放MMAE。随后MMAE与微管蛋白结合，破坏细胞内的微管网络，诱导细胞周期停滞和细胞凋亡。 | SGN-35,cAC10-Val-Cit-MMAE | Brentuximab Vedotin | TNFRSF8/CD30 [Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lebrikizumab | Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease. | MILR1444A,PRO301444 | Lebrikizumab | IL13[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Secukinumab | Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis. | AIN457 | Secukinumab | IL17A[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Rontalizumab | Rontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus. | RhuMAB IFNalpha | Rontalizumab | IFNA1[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Girentuximab | Girentuximab is a monoclonal chimeric (mouse/human) antibody directed against carbonic anhydrase IX, an antigen expressed in 95% of clear cell renal cell carcinomas (RCC). | WX-G250,cG250 | Girentuximab | CA9[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Iodine (124I) Girentuximab | Girentuximab I-124 is under investigation in clinical trial NCT01762592 (REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT). | 124I_WX-G250,124I_cG250 | Iodine (124I) Girentuximab | CA9[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Suvizumab | KD-247 | Suvizumab | HIV-1[Human immunodeficiency virus 1] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Glembatumumab | CDX-011 (DOX),CR011,glembatumumab vedotin (ADC) | Glembatumumab | GPNMB extracellular domain[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Dalotuzumab | Dalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer. | MK-0646 | Dalotuzumab | IGF1R/CD221[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Benralizumab | Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly fully depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma. | BIW-8405,KHK4563,MEDI-563 | Benralizumab | IL5RA/CD12[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Mavrilimumab | Mavrilimumab has been investigated for the treatment of Rheumatoid Arthritis. | CAM-3001 | Mavrilimumab | CSF2RA/CD116 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-lambda2 | info@doronscientific.com |
| Teprotumumab | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor.8 Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received “breakthrough therapy” designation from the FDA in 20163 and was approved by the FDA in January 2020 for the treatment of TED.7 Thyroid eye disease is a potentially debilitating complication of Graves’ Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries – teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease. | RO4858696-000 | Teprotumumab | IGF1R/CD221[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Drozitumab | PRO95780,anti-DR5,rhuMAb DR5 | Drozitumab | TNFRSF10B/TRAILR2/CD262[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Ensituximab | Ensituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer. | NOE-102,NPC-1C | Ensituximab | MUC5AC[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Foralumab | NI-0401 | Foralumab | CD3E[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Itolizumab | T1h | Itolizumab | CD6[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Olaratumab | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016. | 3G3,IMC-3G3,LY3012207 | Olaratumab | PDGFRA/PDGFR2/CD140a[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Olokizumab | Olokizumab has been used in trials studying the treatment of Crohn’s Disease. | CDP 6038 | Olokizumab | IL6[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Oxelumab | R4930,RG4930,RO4989991,huMAb OX40L | Oxelumab | TNFSF4/CD252[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Roledumab | LFB-R593 | Roledumab | RHD[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Samalizumab | Samalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia. | ALXN6000,Anti-CD200,hB7V3V2 G2G4 | Samalizumab | CD200[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-G4-kappa | info@doronscientific.com |
| Trastuzumab Emtansine | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech’s trastuzumab antibody linked to ImmunoGen’s cell-killing agent, DM1. T-DM1 combines two strategies– anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)–to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. | PRO132365,RG3502,T-DM1,trastuzumab-MCC-DM1 | Trastuzumab Emtansine | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Atinumab | 6A3-IgG4,ATI355 | Atinumab | RTN4/NOGO[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Carlumab | Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer. | CNTO 888 | Carlumab | CCL2/MCP-1/MCAF/SCYA2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Enavatuzumab | PDL 192 | Enavatuzumab | TNFRSF12A/CD266[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Enokizumab | A humanized immunoglobulin G1k anti-interleukin-9 mAb. | 7F3com-2H2,MEDI-528 | Enokizumab | IL9[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Etrolizumab | Etrolizumab has been used in trials studying the treatment of Crohn Disease and Ulcerative Colitis. | Anti-Beta7,PRO145223,RG7413,rhuMAb Beta7 | Etrolizumab | ITGA4_ITGB7[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Fulranumab | Fulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others. | 4D4,AMG-403,JNJ-42160443 | Fulranumab | NGF/NGFB[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Icrucumab | Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer). | 18F1,IMC-18F1,LY3012212 | Icrucumab | FLT1/ VEGFR-1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Mogamulizumab | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions 8.On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as Poteligeo) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy 7.Mogamulizumab is derived from Kyowa Hakko Kirin’s POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma 2. | AMG-761,KW-0761 | Mogamulizumab | CCR4/CD194[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Namilumab | Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis. | MT203 | Namilumab | CSF2/GM-CSF[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Onartuzumab | Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others. | MetMAb,OA-5D5,PRO 143966 | Onartuzumab | MET/RCCP2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab-G1-kappa -[Fc-G1] | info@doronscientific.com |
| Ponezumab | Ponezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer’s Disease). | PF-04360365,RN-1219,clone 9TL | Ponezumab | APP Abeta40[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Radretumab | L19-131 I,L19-SIP | Radretumab | FN EDB[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | [(scFv-heavy-kappa)-IGHE-CH4]2 | info@doronscientific.com | |
| Tregalizumab | Tregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis. | BT-061, hB-F5, hBF5(H37L_L4M) | Tregalizumab | CD4[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ublituximab | Ublituximab has been used in trials studying the treatment of B-cell Lymphoma, Neuromyelitis Optica, Mantle Cell Lymphoma, Non-Hodgkins Lymphoma, and Marginal Zone Lymphoma, among others. | LFB-R603, TG-1101,TGTX-1101 | Ublituximab | MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Urelumab | Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer – Solid Tumors and B-Cell Non-Hodgkin’s Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex’s UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. | BMS-663513 | Urelumab | TNFRSF9/CD137 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Vesencumab | Vesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors). | MNRP1685A | Vesencumab | NRP1/VEGF165R extracellular domain[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Blosozumab | Blosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal. | LY2541546 | Blosozumab | SOST(sclerostin)[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Brodalumab | Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn’s Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis. | AMG827,KHK4827 | Brodalumab | IL17RA/CD217[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Crenezumab | Crenezumab has been used in trials studying the treatment of Alzheimer’s Disease. | MABT5102A,RG7412 | Crenezumab | APP Abeta42 and Abeta40[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Ficlatuzumab | Ficlatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid Leukemia, among others. | AV-299,SCH 900105 | Ficlatuzumab | HGF[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ixekizumab | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis.Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. | LY2439821 | Ixekizumab | IL17A [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Narnatumab | Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors). | IMC RON-8,RON8 | Narnatumab | MST1R/CD136[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ozoralizumab | Ozoralizumab has been used in trials studying the treatment of Rheumatoid Arthritis and Active Rheumatoid Arthritis. | ATN-103 | Ozoralizumab | ALB/TNFSF2/TNF-alpha/TNFA [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | VH-VH’-VH | info@doronscientific.com |
| Pateclizumab | Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis). | MLTA3698A,PRO283698,RG7416 | Pateclizumab | LTA/TNFSF1[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Sirukumab | Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid. | CNTO 136 | Sirukumab | IL6 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tabalumab | Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others. | LY2127399 | Tabalumab | TNFSF13B/CD257[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Vatelizumab | Vatelizumab has been used in trials studying the treatment of Ulcerative Colitis. | GBR500 | Vatelizumab | ITGA2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Cantuzumab Ravtansine | IMGN242,huC242-DM4 | Cantuzumab Ravtansine | MUC1 CA242[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Indatuximab Ravtansine | BT-062,nBT062-DM4 | Indatuximab Ravtansine | SDC1/CD138[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Sarilumab | Sarilumab is a fully human anti-IL-6R monoclonal IgG1 antibody that binds to both membrane bound and soluble interleukin 6 (IL-6) receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6 1. Sarilumab was developped by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe Rheumatoid Arthritis (RA) in combination with methotrexate 4. RA is a chronic inflammatory disease characterized by polyarthritis and its treatment has been challenged by the different response in every patient 3. Subcutaneous administration of Sarilumab has been shown to decrease acute-phase reactant levels and improve in clinical RA symptoms 2. | REGN88,SAR153191 | Sarilumab | IL6R/CD126[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Caplacizumab | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,6 and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression. | ALX-0081,PMP12A2h1-linker AAA-PMP12A2h1,caplacizumab-yhdp | Caplacizumab | VWF A1 domain[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | VH-VH | info@doronscientific.com |
| Inclacumab | Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular. | LC1004-002,RO4905417 | Inclacumab | SELP[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Flanvotumab | 20D7S,IMC-20D7S | Flanvotumab | TYRP1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Romosozumab | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies9. Romosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study7,8. In a comparison study of post menopausal women with osteoporosis and a past fracture, romosozumab for 12 months followed by alendronic acid for 12 months was superior to alendronic acid alone for 24 months3. Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide4. Romosozumab is marketed in the United States by Amgen under the brand name Evinity7. Romosozumab was granted FDA approval on April 9,2019. | 785A070802,AMG 785,CDP-7851,romosozumab-aqqg,sclerostin Ab | Romosozumab | SOST[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Solitomab | MT110 | Solitomab | CD3E/EpCAM[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | (scFv-kappa-heavy)-(scFv-heavy-kappa) | info@doronscientific.com | |
| Quilizumab | Quilizumab is under investigation in clinical trial NCT01160861 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis). | 47H4,Anti-M1 prime,MEMP1972A,RG-7449 | Quilizumab | IGHE[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Patritumab | Patritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others. | AMG888,U3-1287 | Patritumab | ERBB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Actoxumab | CDA 1,MBL-CDA1,MDX-066,MK-3415A (combination of actoxumab and bezlotoxumab) | Actoxumab | toxin A[Clostridium difficile] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Bezlotoxumab | Bezlotoxumab is a human monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Used to reduce the recurrence of Clostridium difficle infection in adults receiving antibiotic therapy to treat C. difficile infection and high risk of recurrence. | MK-6072,CDB-1,MDX-1388,MK-3415A (combination of actoxumab and bezlotoxumab),formerly CDB 1 | Bezlotoxumab | toxin B[Clostridium difficile] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Alirocumab | Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood. | REGN727,SAR-236553, | Alirocumab | PCSK9[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Clazakizumab | Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis. | ALD-518,BMS-945429 | Clazakizumab | IL6[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Demcizumab | Demcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung. | OMP-21M18 | Demcizumab | DLL4 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Duligotuzumab | Duligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant. | MEHD7945A,RG-7597, | Duligotuzumab | ERBB3 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Enoticumab | REGN-421,SAR153192 | Enoticumab | DLL4 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Fasinumab | Fasinumab has been used in trials studying the basic science and treatment of Sciatica, Back Pain, Low Back Pain, Osteoarthritis, Hip, and Abdominal Pain Upper, among others. | REGN475,SAR164877 | Fasinumab | NGF/NGFB [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Futuximab | Futuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors). | DS 992,Sym 004 (combination of modotuximab and futuximab) | Futuximab | EGFR domain III /ERBB1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Imgatuzumab | Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer). | GA201,RG7160,RO5083945 | Imgatuzumab | EGFR [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lampalizumab | Lampalizumab has been used in trials studying the treatment of Geographic Atrophy. | AFD, Anti-fD,Anti-FACTOR D,FCFD4514S,RG7417 | Lampalizumab | CFD[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab-G1-kappa | info@doronscientific.com |
| Ligelizumab | Ligelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma and Atopic Dermatitis, among others. | CL-2C | Ligelizumab | IGHE[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lirilumab | Lirilumab has been used in trials studying the treatment of Leukemia, CANCER,NOS, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia, among others. | BMS-986015,IPH2102 | Lirilumab | KIRD2 subgroup[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Nivolumab | Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat advanced (metastatic) non-small cell lung cancer. | BMS-936558,MDX-1106,ONO-4538 | Nivolumab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Ocaratuzumab | AME-133v,LY2469298 | Ocaratuzumab | MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Orticumab | BI-204,MLDL-1278A,R-7418 | Orticumab | oxLDL[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Parsatuzumab | Parsatuzumab is under investigation in clinical trial NCT01366131,Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE). | RG7414,RO5490248 | Parsatuzumab | EGFL7[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Perakizumab | RG4934,RO5310074 | Perakizumab | IL17A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Placulumab | Placulumab has been used in trials studying the treatment of Rheumatoid Arthritis. | ART621,CEP-37247,PN0621 | Placulumab | TNFSF2/TNF-alpha/TNFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | [V-kappa]2-Fc | info@doronscientific.com |
| Simtuzumab | Simtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis. | AB0024,GS-6624 | Simtuzumab | LOXL2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Vorsetuzumab | SGN-70,h1F6 | Vorsetuzumab | CD70/TNFSF7[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Vorsetuzumab Mafodotin | SGN-75 | Vorsetuzumab Mafodotin | CD70/TNFSF7[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Modotuximab | Modotuximab is under investigation in clinical trial NCT03549338 (Sym004 Versus Futuximab or Modotuximab in Patients With mCRC). | DS 1024,Sym 004 (combination of modotuximab and futuximab) | Modotuximab | EGFR/ERBB1 domain III[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Concizumab | Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder. | Anti-TFPI,NN7415,mab2021 | Concizumab | TFPI[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Evolocumab | Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9). | AMG 145,Anti-PCSK9 | Evolocumab | PCSK9[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-lambda | info@doronscientific.com |
| Dupilumab | Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis. | CD124,REGN668,SAR231893 | Dupilumab | IL4R/CD124[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Tildrakizumab | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis 3.The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in March 2018. The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every 12 weeks thereafter 7. A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects 5. |
MK-3222, SCH900222 | Tildrakizumab | IL23A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Dusigitumab | Dusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer. | MEDI-573 | Dusigitumab | IGF1/IGF2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-nd | info@doronscientific.com |
| Nesvacumab | Nesvacumab is under investigation in clinical trial NCT01997164,Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME). | REGN-910 | Nesvacumab | ANGPT2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Pidilizumab | Pidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma). | CT-011 | Pidilizumab | PDCD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ozanezumab | Ozanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting. | GSK-1223249 | Ozanezumab | RTN4/NOGO[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-nd | info@doronscientific.com |
| Seribantumab | Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others. | MM-121,SAR256212 | Seribantumab | ERBB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-lambda | info@doronscientific.com |
| Bimagrumab | Bimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others. | BYM338 | Bimagrumab | ACVR2A/ACVR2B[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Pinatuzumab Vedotin | Pinatuzumab vedotin is under investigation in clinical trial NCT01691898,A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL). | ACD22-VCMMAE,DCDT2980S,FCU2803,RG-7593,RO5541072-000 | Pinatuzumab Vedotin | CD22[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Polatuzumab Vedotin | Polatuzumab vedotin is a CD79b specific antibody conjugated to the antineoplastic agent monomethyl auristatin E.Label This medication was granted accelerated FDA approval on 10 June 2019.5. | ACD79B-VCMMAE,DCDS4501A,FCU2711,RO5541077-000,polatuzumab vedotin-piiq | Polatuzumab Vedotin | CD79B[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Pritoxaximab | Shigamabs-(drug name for the combination of pritoxaximab and setoxaximab),caStx1 | Pritoxaximab | shiga toxin type 1 B subunit[Escherichia coli] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Setoxaximab | Shigamabs-(drug name for the combination of pritoxaximab and setoxaximab),caStx2 | Setoxaximab | Stx2/SLT-II[Escherichia coli] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Lodelcizumab | LGT209,NVP-LGT209 | Lodelcizumab | PCSK9[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Idarucizumab | Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin use, etc).Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations. Its use is associated with immediate, fully and sustained reversal of the anticoagulant effects of dabigatran.Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199. | aDabi-Fab,anti-dabigatran,antidote for dabigatran | Idarucizumab | dabigatran etexilate mesylate[Drug] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab-G1-kappa | info@doronscientific.com |
| Eldelumab | MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis. | BMS-936557,MDX-1100 | Eldelumab | CXCL10[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Dinutuximab | Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the fully eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. | 14.18,MAb-14.18,MOAB Ch14.18 | Dinutuximab | ganglioside GD2[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tosatoxumab | KBSA301 | Tosatoxumab | alpha toxin[Staphylococcus aureus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Codrituzumab | Codrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma). | GC33,RG7686,RO5137382 | Codrituzumab | GPC3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tarextumab | Tarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer. | OMP-59R5 | Tarextumab | CD52[Homo sapiens] | store at -80°C | 100ug and 1mg | Caninized | 1mg/ml | IgG2-kappa-lambda | info@doronscientific.com |
| Guselkumab | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation 2. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis.Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. | CNTO-1959 | Guselkumab | IL23A[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Tovetumab | Tovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies. | MEDI-575 | Tovetumab | PDGFRA / PDGFR2/ CD140a[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Vantictumab | Vantictumab has been used in trials studying the treatment of Solid Tumors, Pancreatic Cancer, and Stage IV Pancreatic Cancer. | OMP-18R5 | Vantictumab | FZD[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-lambda | info@doronscientific.com |
| Anetumab Ravtansine | Anetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer). | BAY 94-9343,unconjugated:BAY 86-1903 | Anetumab Ravtansine | MSLN[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Pembrolizumab | Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy. | MK-3475 | Pembrolizumab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Margetuximab | Margetuximab is under investigation in clinical trial NCT03133988 (Margetuximab Expanded Access Program). | MGAH-22 | Margetuximab | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Anifrolumab | Anifrolumab has been investigated for the treatment of Scleroderma. | MDX-1333,MEDI-546 | Anifrolumab | IFNAR1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Enfortumab Vedotin | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers.It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link.It is similar to brentuximab vedotin, another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4.The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name PadcevTM. | AGS-22CE,AGS-22M,AGS-22M6E,unconjugated:AGS-22C3 or AGSM6 | Enfortumab Vedotin | PVRL4[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lifastuzumab Vedotin | Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer). | DNIB0600A (conjugate),MNIB2126A (non conjugate) | Lifastuzumab Vedotin | SLC34A2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Aducanumab | Aducanumab has been used in trials studying the treatment of Alzheimer’s Disease. | BART,BIIB-037 | Aducanumab | APP Abeta[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Fletikumab | Fletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis). | 15D2,NN-8226,NNC-0109-0012 | Fletikumab | IL20 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Dapirolizumab Pegol | CDP7657 | Dapirolizumab Pegol | CD40LG/CD154[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab’-G1-kappa | info@doronscientific.com | |
| Sofituzumab Vedotin | DMUC5754A (conjugate),MMUC1206A (nonconjugate) | Sofituzumab Vedotin | MUC16/CA125[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Ulocuplumab | BMS-936564, MDX-1338 | Ulocuplumab | CXCR4/CD184[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Ralpancizumab | PF-05335810,RN317 | Ralpancizumab | PCSK9/NARC1/ PC9[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Bococizumab | Bococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia. | PF-04950615,RN-316 | Bococizumab | PCSK9/NARC1/ PC9[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Bimekizumab | Bimekizumab has been used in trials studying the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis. | CDP4940 | Bimekizumab | IL17A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Otlertuzumab | TRU-016 | Otlertuzumab | CD37/TSPAN26[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | VH-V-kappa-CH2-CH3 | info@doronscientific.com | |
| Abituzumab | Abituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic. | DI-17E6,EMD 525797 | Abituzumab | ITGAV /CD51[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Coltuximab Ravtansine | Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL). | SAR3419 | Coltuximab Ravtansine | CD19 [Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ontuxizumab | Ontuxizumab (MORAb-004) is monoclonal antibody that interferes with endosialin (tumor endothelial marker-1). | MORAb-004 | Ontuxizumab | CD248[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Brontictuzumab | OMP-52M51 | Brontictuzumab | NOTCH1[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-lambda | info@doronscientific.com | |
| Denintuzumab Mafodotin | SGN-19A,SGN-CD19A,hBU12-491,unconjugated:huBU12 | Denintuzumab Mafodotin | CD19[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Diridavumab | CR-6261,CR6261 | Diridavumab | influenza A virus hemagglutinin HA2 subunit from various strains[Influenza A virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Abrilumab | Abrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181). | AMG 181,MEDI-7183 | Abrilumab | ITGA4_ITGB7[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Emibetuzumab | Emibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others. | LA480,LY-2875358 | Emibetuzumab | MET/RCCP2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Varlilumab | Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett’s Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others. | 1F5,CDX-1127 | Varlilumab | CD27/TNFRSF7[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Pasotuxizumab | BAY 2010112,BITE MT112,MT-112 | Pasotuxizumab | CD3E/FOLH1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | (scFv-heavy-kappa)-(scFv-heavy-lambda) | info@doronscientific.com | |
| Lulizumab Pegol | Lulizumab pegol is under investigation in clinical trial NCT02843659,Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren’s Syndrome. | BMS-931699 | Lulizumab Pegol | CD28 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | V-kappa | info@doronscientific.com |
| Vanucizumab | Vanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors. | RG-7221,RG7221,RO5520985 | Vanucizumab | ANGPT2/VEGFA[Homo sapiens], | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | VH-C-kappa-CH2-CH3_V-lambda-CH1_H-GAMMA-1_L-kappa | info@doronscientific.com |
| Emactuzumab | Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors). | RG7155,RO5509554 | Emactuzumab | CSF1R/CD115[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lumretuzumab | Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer. | RG-7116,RO5479599 | Lumretuzumab | ERBB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Begelomab | BT 5/9,SAND-26 | Begelomab | DPP4/TP103/CD26[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG2b-kappa | info@doronscientific.com | |
| Imalumab | BAX069,BAX69 | Imalumab | MIF[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Lenzilumab | KB-003 | Lenzilumab | CSF2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Firivumab | CT-P22 | Firivumab | Influenza A virus hemagglutinin HA[Influenza A virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Avelumab | Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. | MSB-0010718C,MSB0010682 | Avelumab | CD274/B7-H1/PDL1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Remtolumab | A-1230717,ABT-122 | Remtolumab | IL17A/TNFSF2/TNF-alpha/TNFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | [VH-VH’-H-Gamma1-VL-VL’-C-kappa]-dimer | info@doronscientific.com | |
| Obexelimab | Obexelimab (XmAb5871) is a first-in-class monoclonal antibody that targets CD19 with its variable domain and uses the XmAb immune inhibitory Fc domain to target FcγRIIb, a receptor that inhibits B cell function. Obexelimab is the first drug candidate to our knowledge that targets FcγRIIb inhibition. | XmAb5871 | Obexelimab | CD19[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lacutamab | IPH4102 | Lacutamab | KIR3DL2[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tafasitamab | MOR-00208,MOR-208,XENP-5574,XMP-5574,XmAb-5574,Xmab-CD19 | Tafasitamab | CD19[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-G2-kappa | info@doronscientific.com | |
| Vobarilizumab | (20A11-9mer-ALB11),ALX-0061 | Vobarilizumab | ALB/IL6R/CD126 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | VH-VH’ | info@doronscientific.com | |
| Atezolizumab | Atezolizumab is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research. | MPDL3280A,RG7446 | Atezolizumab | CD274/B7-H1/PDL1[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lokivetmab | CAN34D3-65,PF-06443537 | Lokivetmab | IL31[Canis lupus familiaris] | store at -80°C | 100ug and 1mg | Caninized | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Durvalumab | Durvalumab (MEDI 4736) is an humanized anti-PD-L1 monoclonal antibody, it fullyly blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.（适用于人源及非人源化小鼠） | MEDI4736 | Durvalumab | CD274/B7-H1/PDL1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Evinacumab | REGN 1500 | Evinacumab | ANGPTL3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Vandortuzumab Vedotin | DSTP-3086S,DSTP3086S,MSTP2109A,RG-7450,RG7450 | Vandortuzumab Vedotin | STEAP1[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Indusatumab Vedotin | Indusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others. | 5F9vcMMAE,MLN-0264,unconjugated:MLN2045 or 5F9 | Indusatumab Vedotin | GUCY2C[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Andecaliximab | GS-5745 | Andecaliximab | MMP9[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Elgemtumab | LJM716,NVS201010 | Elgemtumab | ERBB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tesidolumab | Tesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others. | LFG 316, LFG-316, LFG316 | Tesidolumab | C5[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Brolucizumab | Brolucizumab, also known as RTH258 or ESBA1008,4 is a monoclonal antibody indicated to treat neovascular age related macular degeneration.Brolucizumab was granted FDA approval in October 2019.6. | ESBA-1008,ESBA1008,RTH258 | Brolucizumab | VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | scFv-kappa-heavy | info@doronscientific.com |
| Dectrekumab | QAX-576 | Dectrekumab | IL13[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Nemolizumab | CIM 331 | Nemolizumab | IL31RA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Isatuximab | Isatuximab is IgG1 chimeric monoclonal antibody that targets specific epitopes on the CD38 receptor of plasma cells and can trigger a variety of unique mechanisms of action, including the promotion of programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is expressed at high levels on MM cells and is a cell surface receptor target for antibody therapy in MM and other malignant tumors. | SAR-650984,hu38SB19 | Isatuximab | CD38[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Lilotomab | HH1 | Lilotomab | CD37[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Lutetium (177Lu) Lilotomab Satetraxetan | 177lu-DOTA-HH1 | Lutetium (177Lu) Lilotomab Satetraxetan | CD37/TSPAN26[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Indusatumab | 5F9,MLN2045 | Indusatumab | GUCY2C[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Bermekimab | Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis). | MABp1,Xilonix | Bermekimab | IL1A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Istiratumab | Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer). | MM-005,MM-141 | Istiratumab | ERBB3/IGF1R/CD221[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa -[scFv]2 | info@doronscientific.com |
| Pepinemab | VX-15,VX15/2503 | Pepinemab | SEMA4D[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Obiltoxaximab | ETI-204 | Obiltoxaximab | Anthrax protective antigen[Bacillus anthracis] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Navivumab | CT-P23 | Navivumab | Influenza A virus hemagglutinin HA[Influenza A virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Vadastuximab Talirine | Vadastuximab talirine (SGN-CD33A) is a novel antibody-conjugated drug targeting CD33, which is composed of pyrrole diazoxide dimeric compounds; CD33 is expressed in most patients with acute myeloid leukemia (AML). | SGN-CD33A,h2H12ec-SGD-1910, h2H12ec-mc-val-ala-SGD-1882 | Vadastuximab Talirine | CD33[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Inebilizumab | MEDI-551 | Inebilizumab | CD19[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Pamrevlumab | FG-3019 | Pamrevlumab | CTGF/IGFBP-8[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Cergutuzumab Amunaleukin | CEA-IL-2v,RG7813,RO-6895882 | Cergutuzumab Amunaleukin | CEACAM5/CEA/CD66e[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IG-Gamma1 -[IL2 (interleukin 2, IL-2) 21-153, engineered]1_kappa | info@doronscientific.com | |
| Trevogrumab | Trevogrumab is under investigation in clinical trial NCT02943239 (Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men). | REGN-1033, REGN1033, SAR-391786 | Trevogrumab | MSTN/GDF8[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Opicinumab | Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants). | BIIB-033 | Opicinumab | LINGO1/LRRN6A/LERN1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Labetuzumab Govitecan | Labetuzumab govitecan (IMMU-130) is an antibody drug conjugate that integrates anti-CEACAM5 antibody labetuzumab with cytotoxic drugs (http://www.chemdrug.com/) SN-38. Carcinoembryonic antigens corresponding to antibodies can be detected in plasma (http://www.chemdrug.com/sell/76/) and have high expression in many solid tumors (especially CRC). | IMMU-130,hMN-14-SN-38,hMN-14-SN-38 ADC,hMN14-CL-SN-38 | Labetuzumab Govitecan | CEACAM5/CEA/CD66e[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Sacituzumab Govitecan | IMMU-132,hRS7-SN-38,hRS7-SN-38-ADC,hRS7-[CL-SN-38] | Sacituzumab Govitecan | TACSTD2/M1S1/ EGP-1/TROP2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Clivatuzumab Tetraxetan | hPAM4,hPAM4 IgG-DOTA,hPAM4-DOTA | Clivatuzumab Tetraxetan | MUC1/CD227[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Ascrinvacumab | Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma. | PF-03446962 | Ascrinvacumab | ACVRL1/SKR3/TGF-B/ TSR-I[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Monalizumab | IPH-2201,NN-8765,NNC-0141-0000-0100,NNC-141-01000,anti-NKG2A,humZ270 | Monalizumab | KLRC1/NKG2A/CD159a/CD94[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Bleselumab | Bleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients). | 4D11,ASKP-1240 | Bleselumab | CD40/ TNFRSF5[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Emicizumab | ACE-910,RG6013,hBS910 | Emicizumab | F10/F9 activated form[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Plozalizumab | Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis. | MLN-1202,anti-CCR2,hu1D9 | Plozalizumab | CCR2/CD192[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Risankizumab | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) that is selective for interleukin 23 (IL-23). On April 23, 2019 it was approved by the FDA (as SKYRIZI) for the treatment of moderate-to-severe plaque psoriasis in adults who are clinically considered eligible for systemic therapy or phototherapy for psoriasis.Label This drug has been commercialized through collaboration between the German pharmaceutical company, Boehringer Ingelheim, and Abbvie. | BI 655066,risankizumab-rzaa | Risankizumab | IL23A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Dinutuximab Beta | Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the fully eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. | APN311,CH14.18/CHO,ch14.18 | Dinutuximab Beta | ganglioside GD2[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Rovalpituzumab Tesirine | SC0001-SCX,SC0002 | Rovalpituzumab Tesirine | DLL3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Rovalpituzumab | Rovalpituzumab | DLL3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | ||
| Tisotumab Vedotin | HuMax-TF-ADC, TF-011-MMAE | Tisotumab Vedotin | F3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Ifabotuzumab | KB-004 | Ifabotuzumab | EPHA3/REK4[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tezepelumab | Tezepelumab is under investigation in clinical trial NCT03406078 (Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma). | AMG 157,AMG-157,MEDI-9929,MEDI9929,anti-TSLP-Receptor (TSLP-R; Crl2) | Tezepelumab | TSLP[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-lambda | info@doronscientific.com |
| Rinucumab | REGN-2176,REGN-2176-3 (combination of aflibercept and ricunumab),REGN2176 | Rinucumab | PDGFRB/ PDGFR-1/CD140b[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Mirvetuximab Soravtansine | IMGN853,M9346A-sulfo-SPDB-DM4 | Mirvetuximab Soravtansine | FOLR1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Afasevikumab | MCAF-5352A,NI-1401,RG-7624,RO5553110 | Afasevikumab | IL17A /IL17F[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tisotumab | HuMax-TF | Tisotumab | F3 /CD142[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Landogrozumab | Landogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer. | LY-2495655 | Landogrozumab | MSTN/GDF8[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Tilavonemab | ABBV-8E12, C2N-8E12 | Tilavonemab | MAPT[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Gontivimab | ALX-0171,VR-465 | Gontivimab | RSV glycoprotein F[Respiratory syncytial virus] | store at -80°C | 100ug and 1mg | Lama glama | 1mg/ml | VH-VH-VH | info@doronscientific.com | |
| Bevacizumab Beta | ABP 215 | Bevacizumab Beta | VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Olendalizumab | ALXN1007 | Olendalizumab | C5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-G4-kappa | info@doronscientific.com | |
| Satralizumab | SA-237 | Satralizumab | IL6R[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Cabiralizumab | FPA-008 | Cabiralizumab | CSF1R/CD115[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Xentuzumab | BI 836845 | Xentuzumab | IGF1/IGF2 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Daclizumab Beta | Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. | Daclizumab Beta | IL2RA/CD25[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Enoblituzumab | MG-A271 | Enoblituzumab | CD276/B7-H3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Refanezumab | Refanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients). | GSK-249320 | Refanezumab | MAG/SIGLEC-4A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Mirvetuximab | M9346A | Mirvetuximab | FOLR1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Blontuvetmab | AT-004,VT-007 | Blontuvetmab | MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Caninized | 1mg/ml | IgG2-kappa-lambda | info@doronscientific.com | |
| Tamtuvetmab | AT-005,AT005 | Tamtuvetmab | NGF/NGFB[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-nd | info@doronscientific.com | |
| Crotedumab | Crotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2. | REGN-1193 | Crotedumab | GCGR[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Rivabazumab | BA1126 | Rivabazumab | PcrV[Pseudomonas aeruginosa,Gram negative bacteria] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab’-G1-kappa | info@doronscientific.com | |
| Navicixizumab | Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors). | OMP-305B83 | Navicixizumab | DLL4/VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Prezalumab | AMG 557,MEDI-5872 | Prezalumab | ICOSLG/B7-H2/B7RP-1/CD275[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Laprituximab Emtansine | IMGN-289,J2898A-SMCC-DM1 | Laprituximab Emtansine | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Laprituximab | J2898A | Laprituximab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Naratuximab Emtansine | IMGN-529,K7153A-SMCC-DM1 | Naratuximab Emtansine | CD37/TSPAN26[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Naratuximab | K7153A | Naratuximab | CD37/TSPAN26[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Vadastuximab | h2H12ec | Vadastuximab | CD33/SIGLEC3[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Carotuximab | TRC-105,c-SN6j | Carotuximab | ENG[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Timolumab | 8c10,BTT-1023,BTT1023,SI-3106,SI-636,r8c10 | Timolumab | AOC3/VAP1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Lanadelumab | Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. The FDA and EU granted the designation of priority review, breakthrough therapy and orphan drug for rare diseases based on the results of the reported clinical trials.Lanadelumab was developed by Shire and FDA approved on August 28, 2018.5. | X124-G01,DX-2930 | Lanadelumab | KLKB1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Vonlerolizumab | MOXR-0916,MOXR0916,RG-7888,RO7021608 | Vonlerolizumab | TNFRSF4/CD134[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Galcanezumab | LY2951742/galcanezumab is a fully humanized monoclonal antibody against human calcitonin gene-related peptide (CGRP) that is developed by ELi Lilly and Company.This therapy is given as a single subcutaneous injection twice a month and ongoing clinical trials for the agent are for episodic and chronic migraine as well as cluster headaches. | LY-2951742,galcanezumab-gnlm | Galcanezumab | CALCA/CGRP1/CALCB/CGRP2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Domagrozumab | PF-06252616 | Domagrozumab | MSTN /GDF8[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Erenumab | Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine . | AMG 334,erenumab-aooe | Erenumab | CALCRL/CGRP-R[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-lambda | info@doronscientific.com |
| Birtamimab | 2A4,ELT1-01,NEOD-001 | Birtamimab | SAA1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric；Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Suptavumab | H1H3592P3,REGN 2222,SAR-438584,SAR438584 | Suptavumab | RSV glycoprotein F[Respiratory syncytial virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Setrusumab | Setrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density). | BPS-804,MOR-05813 | Setrusumab | SOST[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-lambda | info@doronscientific.com |
| Iodine (131I) Apamistamab | Iomab-B | Iodine (131I) Apamistamab | PTPRC/CD45[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Duvortuxizumab | JNJ-64052781,MGD011,RES192M1.2 | Duvortuxizumab | CD19/CD3E[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric；Humanized | 1mg/ml | scFv -h-CH2-CH3(_scFv)_h-CH2-CH3 | info@doronscientific.com | |
| Rozanolixizumab | Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy). | UCB-7665 | Rozanolixizumab | FCGRT[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Lupartumab | BAY 1112623 | Lupartumab | LYPD3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Depatuxizumab | Depatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors. | ABT-806 | Depatuxizumab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric；Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Depatuxizumab Mafodotin | Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme. | ABT-414,unconjugate:ABT-806 | Depatuxizumab Mafodotin | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric；Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Fremanezumab | LBR-101,PF-04427429,RI-307,RN-307,TEV-48125,fremanezumab-vfrm | Fremanezumab | CALCA /CALCB[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Burosumab | KRN-23,UX-023 | Burosumab | FGF23[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Eptinezumab | Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals.7 Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).8,1,2,3 It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults. | ALD-403 | Eptinezumab | CALCA /CALCB[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Gemtuzumab Ozogamicin | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody Label. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. | CDP-771,CMA-676,WAY-CMA-676 | Gemtuzumab Ozogamicin | CD33[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Elezanumab | ABT-555,AE12-1Y-QL(derived from parental mAb AE12-1 and AE12-1Y) | Elezanumab | RGMA[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Lutikizumab | ABT-981 | Lutikizumab | IL1A /IL1B[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | [VH-VH’-H-Gamma1-VL-VL’-C-kappa]-dimer | info@doronscientific.com | |
| Dezamizumab | GSK-2398852 | Dezamizumab | APCS[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Telisotuzumab Vedotin | ABBV-399,ABT-700-vcMMAE | Telisotuzumab Vedotin | MET/RCCP2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Telisotuzumab | ABT-700,hz224G11 | Telisotuzumab | MET/RCCP2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Aprutumab | BAY 1179470 | Aprutumab | FGFR2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Aprutumab Ixadotin | BAY 1187982 | Aprutumab Ixadotin | FGFR2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Utomilumab | Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer). | PF-05082566, PF-2566 | Utomilumab | TNFRSF9/CD137[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-lambda | info@doronscientific.com |
| Vunakizumab | SHR-1314 | Vunakizumab | IL17A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Camrelizumab | Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy). | SHR-1210 | Camrelizumab | PDCD1/PD-1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Rosmantuzumab | OMP-131R10 | Rosmantuzumab | RSPO3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Sacituzumab | hRS7 | Sacituzumab | TACSTD2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Ranevetmab | NV-01 | Ranevetmab | NGF/NGFB[Mus musculus] | store at -80°C | 100ug and 1mg | Caninized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Brazikumab | AMG-139,MEDI2070 | Brazikumab | IL23A[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-lambda | info@doronscientific.com | |
| Lupartumab Amadotin | BAY 1129980 | Lupartumab Amadotin | LYPD3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Emapalumab | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.1,5 The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough therapy.5 As well, emapalumab was given the status of PRIME by the EMA. | NI-0501,emapalumab-lzsg | Emapalumab | IFNG [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Crizanlizumab | SelG1 | Crizanlizumab | SELP[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Trastuzumab Duocarmazine | SYD985,trastuzumab vc-seco-DUBA (trastuzumab valine-citrulline-seco-duocarmycinhydroxybenzamide-azaindole) | Trastuzumab Duocarmazine | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Ravulizumab | Ravulizumab is considered a long-acting complement 5 (C5) inhibitor that has been undergoing clinical trials for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) as of 4 February, 2016. A drug similar to ravulizumab (ALXN1210), called eculizumab, is currently approved for the treatment of PNH in 46 countries under the brand name Soliris®. Ravulizumab is considered by Alexion Pharmaceuticals Inc. to be a “next-generation” eculizumab molecule. Ravulizumab was subsequently approved by the US FDA in December of 2018 for a variety of beneficial characteristics that make it an advanced, next-generation agent in comparison to eculizumab. In particular, ravulizumab is currently the first and only long-acting C5 complement inhibitor that can be administered every eight weeks for the treatment of adult patients with PNH whereas eculizumab is a bi-weekly treatment,Label. Moreover, virtually all of the phase 3 trial results for ravulizumab have demonstrated the equivalent efficacy and safety established by eculizumab and that patients transition safely and effectively from using eculizumab to ravulizumab. Subsequently, whereas PNH patients may have needed to previously plan their lives rather strictly around the bi-weekly infusion administrations of eculizumab, with ravulizumab such patients can find a more relaxed dosing schedule of only six or seven infusions over an entire year,Label. | ALXN-1210,ravulizumab-cwvz | Ravulizumab | C5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG2-G4-kappa | info@doronscientific.com |
| Tomaralimab | Tomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function). | OPN-305 | Tomaralimab | TLR2/CD282[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Maftivimab | REGN3470-3471-3479 | Maftivimab | Zaire Ebola virus[Zaire ebolavirus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Garetosmab | REGN2477 | Garetosmab | INHBA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Flotetuzumab | MGD-006,MGD006,RES234,S80880 | Flotetuzumab | CD3E/IL3RA/CD123[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus;Humanized | 1mg/ml | VH-VL-VH’-VL’ | info@doronscientific.com | |
| Losatuxizumab Vedotin | ABBV-221 | Losatuxizumab Vedotin | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Losatuxizumab | ABT-806,PR-1316749 | Losatuxizumab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Varisacumab | AT-001,GNR-011,r84 | Varisacumab | VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Letolizumab | BMS-986004 | Letolizumab | CD40LG/CD154[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | (VH-CH2-CH3)2 | info@doronscientific.com | |
| Suvratoxumab | Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893). | MEDI4893 | Suvratoxumab | alpha toxin[Staphylococcus aureus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Frunevetmab | NV-02 | Frunevetmab | NGF/NGFB[Mus musculus] | store at -80°C | 100ug and 1mg | Felinized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Lesofavumab | MHAB5553A,RG70026,RO7045557 | Lesofavumab | Influenza B virus hemagglutinin[Influenza B virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Gedivumab | Gedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers). | MHAA4549A,RO6876802;RG7745 | Gedivumab | Influenza A virus hemagglutinin HA[Influenza A virus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Azintuxizumab | ABBV-383,PR-1471272 | Azintuxizumab | SLAMF7/CRACC/CD319[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric;Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Azintuxizumab Vedotin | ABBV-838 | Azintuxizumab Vedotin | SLAMF7/CRACC/CD319[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric;Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Trastuzumab Deruxtecan | Trastuzumab deruxtecan is HER2-targeted antibody-coupled drug (ADC) for patients with HER2-positive metastatic breast cancer who have previously received two or more anti-HER2 treatments. | DS-8201,DS-8201a | Trastuzumab Deruxtecan | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Selicrelumab | CP-870,893,RG-7876,RO-7009789 | Selicrelumab | CD40/TNFRSF5[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Lacnotuzumab | MCS-110 | Lacnotuzumab | CSF1/MCSF[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Gilvetmab | AH-PD1 | Gilvetmab | PDCD1/PD1/CD279[Canis lupus familiaris] | store at -80°C | 100ug and 1mg | Caninized | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Cosfroviximab | c13C6-FR1-N | Cosfroviximab | Zaire Ebola virus [Zaire ebolavirus] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Porgaviximab | c2G4-N | Porgaviximab | Zaire Ebola virus[Zaire ebolavirus] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Larcaviximab | c4G7-N | Larcaviximab | Zaire Ebola virus[Zaire ebolavirus] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Oleclumab | MEDI-9447 | Oleclumab | NT5E/CD37[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Zanidatamab | ZW-25,ZW25 | Zanidatamab | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa/scFv-h-CH2-CH3 | info@doronscientific.com | |
| Tomuzotuximab | CetuxiMab-GEX,GEXMab52201 | Tomuzotuximab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Timigutuzumab | GEXMab73,GT-MAb7.3-GEX,TrastuzuMab-GEX | Timigutuzumab | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Gatipotuzumab | PankoMab,PankoMab-GEX,hPankoMab | Gatipotuzumab | MUC1/CD227[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Loncastuximab Tesirine | ADCT-402,RB4v1.2-SG-3249 | Loncastuximab Tesirine | CD19[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Zolbetuximab | Zolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer). | GC-182,IMAB-362,IMAB362,claudiximab | Zolbetuximab | CLDN18[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Talacotuzumab | Talacotuzumab, also known as JNJ-56022473 (and formerly CSL-362) is a humanized IgG1 monoclonal antibody designed to bind to and neutralize CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. | CSL-362-AML,CSL362,JNJ-56022473 | Talacotuzumab | NOTCH2/ NOTCH3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Sirtratumab | AGS15C,Ha15-10ac12,Ha15-10ac12.1 | Sirtratumab | SLITRK6[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Gimsilumab | Gimsilumab is a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF). | MORAb-022 | Gimsilumab | CSF2 /GM-CSF[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tislelizumab | Tislelizumab (BeiGene) is a humanized monoclonal antibody that was designed to bind to the PD-1 receptor and prevent binding of PD-L1. In addition, tislelizumab was designed to minimize binding to Fc-gamma-receptors (FcyR) on macrophages. Preclinical studies found that binding to FcyR on macrophages compromises the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. | BGB-A317 | Tislelizumab | PDCD1/PD1/ CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Ianalumab | Ianalumab (VAY736) is monoclonal antibody that depletes B cells and blocks B cell activation factor receptors. | VAY-736 | Ianalumab | TNFRSF13C/CD268[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Loncastuximab | RB4v1.2 | Loncastuximab | CD19 [Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Mosunetuzumab | Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3ε), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing. | BTCT4465A,RG-7828,RO7030816 | Mosunetuzumab | CD3E/MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Spartalizumab | Spartalizumab (PDR001) is humanized IgG4 monoclonal antibody that targets binding to PD-1 with sub-nanomolar affinity to block its interaction with PD-L1 / PD-L2, thereby preventing PD-1 mediated inhibitory signals Transduction leads to T cell activation. | NPVPDR001,NVS240118,PDR001 | Spartalizumab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Ladiratuzumab | hLIV22 | Ladiratuzumab | SLC39A6[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Atidortoxumab | ASN-1,ASN-100 (combination of atidortoxumab and berlimatoxumab) | Atidortoxumab | alpha toxin[Staphylococcus aureus];bi-component leukocidins [Staphylococcus aureus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Berlimatoxumab | ASN-100 (combination of atidortoxumab and berlimatoxumab),ASN-2 | Berlimatoxumab | LukGH[Staphylococcus aureus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tiragolumab | Tiragolumab is fully humanized monoclonal antibody. Tiragolumab targets TIGIT and directly or indirectly activates anti-tumor immune responses by acting on the activation pathways of APC and T cells and NK cells to achieve the purpose of eliminating tumor cells. | MTIG-7192-A,MTIG-7192A,MTIG7192A,RG-6058,RO-7092284,RO7092284 | Tiragolumab | TIGIT/VSIG9/VSTM3[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Iladatuzumab | MCDS0593A,RO7032005 | Iladatuzumab | CD79B[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Mirikizumab | Mirikizumab is humanized IgG4 monoclonal antibody that targets p19 subunit binding to IL-23. Currently, mirikizumab is being developed for a variety of immune diseases, including psoriasis, UC, and Crohn’s disease (CD), of which the treatment of moderate to severe plaque psoriasis is already in phase III clinical practice. | LY-3074828 | Mirikizumab | IL23A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Cofetuzumab | PF-06523435,hu24 | Cofetuzumab | PTK7[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Prasinezumab | Prasinezumab (PRX002/RG7935) is an investigational monoclonal antibody that targets α-synuclein, a protein that is believed to misfold and aggregate to form the protein structures that are highly implicated in Parkinson’s disease pathology.Prasinezumab targets α-synuclein and is being developed through a worldwide collaboration with Roche as a potentially disease modifying therapy that is designed to slow or reduce the neurodegeneration associated with α-synuclein misfolding and/or its transmission. | PRX002,RG-7935 | Prasinezumab | SNCA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Bemarituzumab | Bemarituzumab is subtype-selective humanized monoclonal antibody against FGFR2b. The FIGHT study aims to evaluate the efficacy of its combination chemotherapy in untreated advanced gastric cancer or gastroesophageal junction cancer. | FPA-144,FPA114-A | Bemarituzumab | FGFR2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Zenocutuzumab | Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer). | MCLA-128,PB4188,R040517 | Zenocutuzumab | ERBB2/ERBB3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Sirtratumab Vedotin | AGS-15E,AGS-15vcMMAE,AGS15C SGD-1006,ASG-15ME,Ha15-10ac.1vcMMAE | Sirtratumab Vedotin | SLITRK6[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Ladiratuzumab Vedotin | Ladiratuzumab vedotin is an antibody-drug conjugate (ADC) that we are developing for the treatment of breast cancer. Most metastatic breast cancers express LIV-1, which also has been detected in a number of other cancers, including melanoma, prostate, ovarian, uterine, and cervical cancers. Ladiratuzumab vedotin consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC agent is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response. | SGN-LIV1A | Ladiratuzumab Vedotin | SLC39A6[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Iladatuzumab Vedotin | DCDS0780A,RO7032005 | Iladatuzumab Vedotin | CD79B[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Camidanlumab Tesirine | Camidanlumab tesirine (ADCT-301) is an antibody-drug conjugate (ADC) combining Genmab’s HuMax®-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. Camidanlumab tesirine targets CD25, which is expressed on a variety of hematological tumors and shows limited expression on normal tissues, except for regulatory T cells (Tregs), which are known to be immunosuppressive. Camidanlumab tesirine is in development under an agreement between Genmab and ADC Therapeutics, under which Genmab owns 25% of the product rights. | ADCT-301,HuMax-TAC-ADC | Camidanlumab Tesirine | IL2RA[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tibulizumab | Tibulizumab is a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. | LY 3090106,LY-3090106,LY3090106 | Tibulizumab | IL17A/TNFSF13B/CD257[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa-[scFv]2 | info@doronscientific.com |
| Cofetuzumab Pelidotin | Anti-PTK7 ADC,PF-06647020,PTK7-ADC | Cofetuzumab Pelidotin | PTK7[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Narsoplimab | Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection. Importantly, inhibition of MASP-2 does not appear to interfere with the classical complement pathway, a critical component of the acquired immune response to infection. This novel, proprietary drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity. | OMS721 | Narsoplimab | MASP2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-lambda | info@doronscientific.com |
| Relatlimab | Relatlimab targets LAG-3. LAG-3 only helps to increase the activity of T cells against tumors, but also inhibits other T cells. | BMS-986016,ONO-4482 | Relatlimab | LAG3/CD223[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Crovalimab | Crovalimab,a Sequential Monoclonal Antibody Recycling Technology (SMART) antibody was engineered for extended self-administered subcutaneous dosing of small volumes in diseases amenable for C5 inhibition. | RG-6107,RO7112689,SKY-59 | Crovalimab | C5[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric;Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Belantamab Mafodotin | Belantamab mafodotin, also known as GSK2857916, is an immunoconjugate that contains humanized anti-BCMA monoclonal antibody, a linker, and the cytotoxic agent auristatin F. It specifically kills cancer cells by targeting BCMA to deliver cytotoxic agents specifically to MM cells. | 2857916,GSK2857916 | Belantamab Mafodotin | TNFRSF17[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ontamalimab | Ontamalimab (SHP 647) is fully human IgG2 monoclonal antibody against mucosal localization protein cell adhesion molecule (MADCAM1). | PF-00547659,PF-547659,SHP647 | Ontamalimab | MADCAM1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Adalimumab Beta | Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α). | ABP 501 | Adalimumab Beta | TNF/TNFSF2/TNF-alpha[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Trastuzumab Beta | Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2.Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer. | ABP 980, ABP-980 | Trastuzumab Beta | ERBB2/EGFR2/CD340 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Netakimab | BCD-085 (Netakimab, trade mark Efleira®) is recombinant human anti-interleukin-17 (IL-17) monoclonal antibody. IL-17 is an inflammation-related cytokine. When its function is abnormal, it will cause autoimmunity and inflammatory diseases. | AG1-25 | Netakimab | IL17A[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens,Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Cusatuzumab | Cusatuzumab is SIMPLE antibody targeting CD70, which is an immune checkpoint target involving hematological malignancies, various solid tumors, and various autoimmune diseases. cusatuzumab aims to block CD70 by killing CD70-expressing cancer cells through complement-dependent cytotoxicity, enhancing antibody-dependent cell-mediated phagocytosis and enhancing antibody-dependent cell-mediated cytotoxicity Immunological monitoring of solid tumors. | ARGX-110 | Cusatuzumab | CD70/TNFSF7[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Faricimab | Faricimab (RG7716) is bispecific antibody drug that simultaneously targets Angiopoietin-2 (Ang-2) and VEGF-A. | RG7716,RO6867461 | Faricimab | ANGPT2/VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens;Humanized | 1mg/ml | IgG1-kappa-lambda | info@doronscientific.com |
| Romilkimab | SAR156597,huTBTI3_2_1 | Romilkimab | IL13/IL4[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | [VH-VH’-H-Gamma1-VL-VL’-C-kappa]-dimer | info@doronscientific.com | |
| Cibisatamab | Cibisatamab (CEA-TCB) is T cell bispecific antibody that binds to carcinoembryonic antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab has one single CD3 epsilon chain binding site and two CEA binding sites on T cells (which regulates the binding affinity to cancer cells with high expression of CEA on the cell surface). This avoids targeting healthy epithelial cells with low CEA expression levels. T cell activation is triggered by binding to CEA on the surface of cancer cells and CD3 on T cells, cytokine secretion and release of cytotoxic particles. | CEA TCB,RG-7802,RO-6958688 | Cibisatamab | CD3E/CEACAM5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa/lambda with domain crossover | info@doronscientific.com |
| Iscalimab | Iscalimab (CFZ533) is fully human monoclonal antibody targeting differentiation cluster 40 (CD40), which cy pathway, preventing CD40 pathway signaling and CD40 + cell type activation It has become a new therapy for the treatment of solid organs and related autoimmune diseases. | CFZ-533,NVP-CFZ533,OM11-62MF | Iscalimab | CD40/TNFRSF5[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Bersanlimab | BI-505 | Bersanlimab | ICAM1/CD54[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Vopratelimab | Vopratelimab is IgG1 ICOS antibody. Studies shows that vopratelimab can activate both effector T cells and suppress intratumoral regulatory T cells (Treg cells) that weaken the immune response. | JTX-2011 | Vopratelimab | ICOS/CD278[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Sutimlimab | Sutimlimab is anti-C1s antibody, and studies have shown that it can significantly increase hemoglobin levels in patients with primary cold agglutinin disease. Cold agglutinin disease (CAD) is an acquired autoimmune hemolytic anemia (AIHA). In cold environments, clinical symptoms related to erythrocyte agglutination occur in cold parts of the body (for example, net Cyanosis or cyanosis of extremities) and hemolytic anemia. | BIVV009,IPN-009,TNT009 | Sutimlimab | C1S[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Etigilimab | Etigilimab is human-derived monoclonal antibody. Etigilimab targets TIGIT. It started clinical research for the treatment of advanced solid tumors in the United States in 2017 and is currently in clinical phase I. | OMP-313M32 | Etigilimab | TIGIT/VSTM3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Abrezekimab | CDP7766,UCB-4144,VR-942 | Abrezekimab | IL13[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab-G1-kappa | info@doronscientific.com | |
| Lenvervimab | Lenvervimab (GC1102) is recombinant hepatitis B immunoglobulin developed by the Korean biopharmaceutical company GCPharma. It aims to reduce blood HBsAg levels to improve the sustained virological response, thereby improving the therapeutic effect. | GC-1102 | Lenvervimab | HBV[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Ravagalimab | ABBV-323 | Ravagalimab | CD40/TNFRSF[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Leronlimab | Leronlimab (PRO140) is humanized IgG4 monoclonal antibody that can target blocking chemokine receptor 5 (CCR5), which is a cellular receptor that is involved in HIV infection, tumor metastasis, and immune signal transduction Play multiple roles. | HuPRO-140,PA-14,PRO-140 | Leronlimab | CCR5/CD195[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Imaprelimab | PRX-003 | Imaprelimab | MCAM[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Cetrelimab | Cetrelimab (JNJ-63723283) is a Programmed Cell Death Receptor-1 (PD-1) Inhibitor. | JNJ-63723283 | Cetrelimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Onvatilimab | JNJ-61610588 | Onvatilimab | VSIR[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Mitazalimab | Mitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study). | ADC-1013,JNJ-64457107 | Mitazalimab | CD40/TNFRSF5[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Tepoditamab | MCLA-117, PB9122 | Tepoditamab | CD3E/CLEC12A[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Enapotamab | Enapotamab | AXL[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | ||
| Enapotamab Vedotin | Enapotamab vedotin (HuMax®-AXL-ADC) is an antibody-drug conjugate (ADC) targeted to AXL. AXL is a unique receptor tyrosine kinase (RTK) that is aberrantly expressed in many solid tumor types and is implicated in tumor cell proliferation,migration, and invasion. | HuMax-AXL-ADC | Enapotamab Vedotin | AXL[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Samrotamab Vedotin | ABBV-085,PR-1498487-MMAE | Samrotamab Vedotin | LRRC15[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Samrotamab | PR-1498487 | Samrotamab | LRRC15[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Belantamab | Belantamab mafodotin (GSK2857916) is antibody-conjugated drug that connects humanized anti-BCMA antibodies with cytotoxic agents, and specifically targets BCMA to deliver cytotoxic agents into MM cells to kill cancer cells effect. | 2857916,GSK2857916,J6M0,J6M0-mcMMAF | Belantamab | TNFRSF17/CD269[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Olinvacimab | Olinvacimab is currently in phase II trials for a combination therapy to treat cancer with Merck’s Keytruda. | SSS-23,TTAC-0001,tanibirumab | Olinvacimab | KDR/VEGFR2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa-lambda | info@doronscientific.com |
| Murlentamab | Murlentamab is monoclonal antibody that binds AMHRII (cell membrane) and CD16 (macrophage surface) with high affinity. | 3C23K,GM102 | Murlentamab | AMHR2[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Abelacimab | NVS250519 | Abelacimab | F11[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Budigalimab | ABBV-181,PR-1648817 | Budigalimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric；Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Cemiplimab | Cemiplimab is fully human PD-1 antibody. The first indication for marketing application is metastatic / local advanced squamous cell carcinoma (Cutaneous Squamous Cell Carcinoma, CSCC). It is an intravenous immunotherapy targeting the PD-1 pathway that can help the immune system fight cancer cells. | REGN-2810,SAR-439684,cemiplimab-rwlc | Cemiplimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Dilpacimab | ABT-165,PR-1283233 | Dilpacimab | DLL4/VEGFA[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Dostarlimab | Dostarlimab (TSR-042) is humanized anti-PD-1 monoclonal antibody jointly developed by TESARO and AnaptysBio. It binds to the PD-1 receptor with high affinity, thereby blocking its binding to PD-L1 and PD-L2 ligands. | ANB-011,TSR-042 | Dostarlimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Frovocimab | Antibody drug targeting PCSK9 | LY-3015014 | Frovocimab | PCSK9[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Gosuranemab | Gosuranemab (BIIB092) is humanized IgG4 monoclonal anti-body that targets N-terminal tau protein (eTau). The basic principle of this treatment is based on the hypothesis that eTau is involved in the spread of pathological diseases. | BMS-986168,IPN-002,huIPN-002 | Gosuranemab | MAPT[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Marstacimab | Marstacimab is fully human monoclonal antibody that binds to and neutralizes TPFI activity and is under development for treatment of hemophilia. Marstacimab is a laboratory-engineered monoclonal antibody designed to treat hemophilia A and B patients, with or without inhibitors. It works by blocking and effectively preventing TFPI from performing the anticoagulant function that it naturally carries out in the human body. | PF-06741086 | Marstacimab | TFPI[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Nirsevimab | MEDI-8897 | Nirsevimab | RSV[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Orilanolimab | SYNT-001 | Orilanolimab | FCGRT[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Omburtamab | Omburtamab is monoclonal antibody targeting B7-H3 antigen expressed in a variety of human solid tumors. Omburtamab (alias: 8H9, formerly known as Burtomab) is a monoclonal antibody linked to radioisotope and capable of binding to the B7-H3 antigen on the surface of neuroblastoma cells. Direct injection into cerebrospinal fluid, bypassing the blood-brain barrier, accurately targeting neuroblastoma in the central nervous system, to avoid damage to other tissues (such as learning disabilities and developmental delays often caused by conventional radiotherapy outside the brain). | 8H9,Mab 8H9 | Omburtamab | CD276/B7-H3/B7RP-2[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Prolgolimab | BCD-100 (Prolgolimab) this product is recombinant human anti-PD-1 monoclonal antibody. | BCD-100 | Prolgolimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens,Chimeric | 1mg/ml | IgG1-kappa-lambda | info@doronscientific.com |
| Osocimab | Osocimab is long-acting, fully human monoclonal antibody that inhibits factor XIa. | BAY 1213790 | Osocimab | F11[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Rolinsatamab | PR-1594804,h16f | Rolinsatamab | PRLR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Sintilimab | Sintilimab is fully human anti-PD-1 antibody used for tumor immunotherapy. It adopts the IgG4 molecular framework and has its hinge region sequence modified (S228P). Sindilimum acts as a blocker of programmed death receptor 1 (PD-1), which can bind to PD-1 molecule on the surface of T cells and release the inhibitory effect of the PD-1 pathway on T cells. | IBI-308 | Sintilimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Spesolimab | BI655130 (Spesolimab) is humanized monoclonal IgG1 antibody (mAb) against IL36R. | BI 655130 | Spesolimab | IL36RN[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tabituximab | ONC-005,OTSA101 | Tabituximab | FZD10[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Temelimab | Temelimab is monoclonal antibody designed to neutralize the pathogenic envelope protein pHERV-W Env encoded by the HERV-W member of the human endogenous retrovirus family. This protein plays a key role in the development of MS, and may also be a key factor in the onset and development of type 1 diabetes. | GNbAC-1, GNbAC1 | Temelimab | HERV and MRSV envelope protein[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Toripalimab | Toripalimab is humanized monoclonal antibody targeted at programmed death receptor 1 (PD-1), used to treat patients with unresectable or metastatic melanoma who have failed previous systemic system therapy, and is intended for treatment Breast cancer, lymphoma, malignant melanoma, urogenital cancer and other types of solid tumors. | Toripalimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Zampilimab | UCB-7858, UCB7858 | Zampilimab | TGM2[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Gancotamab | Gancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician’s Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients). | MM-302 | Gancotamab | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | scFv-heavy-lambda | info@doronscientific.com |
| Rolinsatamab Talirine | ABBV-176,DC-1630993,h16f | Rolinsatamab Talirine | PRLR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tabituximab Barzuxetan | OTSA101-DTPA-90Y,OTSA101-DTPA,OTSA101-SS01 | Tabituximab Barzuxetan | FZD10[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Mezagitamab | TAK-079 | Mezagitamab | CD38 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Cobolimab | Cobolimab is antibody drug against TIM3. | TSR-022 | Cobolimab | HAVCR2/TIM3/CD366[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Levilimab | BCD-089 | Levilimab | IL6R[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Etokimab | Etokimab,previously known as ANB020,is an antibody that inhibits the activity of IL-33,a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases. | ANB020 | Etokimab | IL33[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Naxitamab | Naxitamab is humanized monoclonal antibody that targets GD2 antigen. GD2 antigen is expressed on the surface of tumors generated by neuroectoderm, including tumors such as neuroblastoma, melanoma, and osteosarcoma. Naxitamab can trigger antibody-mediated cytotoxicity and activate the complement system in the immune system by binding to the GD2 antigen on the surface of the tumor, thereby achieving the effect of killing the tumor. | Hu3F8 | Naxitamab | Ganglioside GD2[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Vofatamab | Vofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma). | MFGR1877S | Vofatamab | FGFR3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Donanemab | Donanemab (LY3002813 or N3pG-Aβ monoclonal antibody) is under development in Alzheimer’s disease. | LY3002813 | Donanemab | APP[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Teclistamab | JNJ-64007957 | Teclistamab | MS4A1[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | Fab-G2b-kappa | info@doronscientific.com | |
| Disitamab Vedotin | RC48 (disitamab vedotin) indication is HER2-positive locally advanced or metastatic urothelial carcinoma. RC48 is the first antibody-drug conjugate (ADC) to enter clinical research in China. ADC are made up of monoclonal antibodies, linkers and toxins, which can precisely attack cancer cells like precision-guided missiles. RC48 targets the HER2 protein on the surface of tumors and can accurately identify and bind to cancer cells, penetrate the cell membrane into its interior, and kill cancer cells. | RC48 | Disitamab Vedotin | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Pozelimab | Pozelimab is research-based, fully human monoclonal antibody, invented using Regeneron’s proprietary VelocImmune technology, which aims to block the complement signaling pathway by binding to complement factor C5. It also prevents the destruction (hemolysis) of red blood cells that cause paroxysmal nocturnal hemoglobinuria and other disease symptoms. | REGN-3918 | Pozelimab | C5[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Glenzocimab | ACT-017 | Glenzocimab | GP6[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | Fab-G1-kappa | info@doronscientific.com | |
| Serclutamab Talirine | ABBV-321 | Serclutamab Talirine | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Serclutamab | DC-1630423,PR-1594407 | Serclutamab | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tamrintamab Pamozirine | DC-1728001,SC-003,SC-003 ADC | Tamrintamab Pamozirine | Adenocarcinoma antigen[Homo sapiens] | store at -80°C | 100ug and 1mg | Mus musculus | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tamrintamab | SC-003 mAb,SC-Mab003,SC34.28ss1 | Tamrintamab | CD3 epsilon /TNFRSF17[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens,Chimeric | 1mg/ml | IgG4-lambda | info@doronscientific.com | |
| Cetuximab Sarotalocan | cetuximab-IR700 | Cetuximab Sarotalocan | EGFR[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Elipovimab | Elipovimab (formerly GS-9722;PGT121-derived broadly neutralizing antibody). | GS-HIV | Elipovimab | HIV-1 gp120[Human immunodeficiency virus 1] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Volagidemab | AMG 477,REMD-477 | Volagidemab | GCGR[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Cendakimab | 13C5.5,ABT-308,RPC-4046 | Cendakimab | IL13[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Balstilimab | PD-1 monoclonal antibody balstilimab is used to treat cervical cancer, balstilimab monotherapy and anti-CTLA-4 monoclonal antibody zalifrelimab combined with balstilimab for metastatic cervical cancer. | AGEN2034 | Balstilimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Zalifrelimab | Balstilimab combined with zalifrelimab in the treatment of metastatic cervical cancer. | AGEN1884 | Zalifrelimab | CTLA4/CD152[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Garadacimab | CSL312 | Garadacimab | F12[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-lambda | info@doronscientific.com | |
| Magrolimab | Magrolimab is anti-CD47 monoclonal antibody designed to promote phagocytosis of cancer cells by macrophages. Its purpose is to interfere with the recognition of CD47 by SIRPα receptors on macrophages, thereby blocking the self-protection signals used by cancer cells to avoid being swallowed by macrophages. | Hu5F9-G4 | Magrolimab | CD47 [Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Ieramilimab | Antibody drugs targeting LAG3, Ieramilimab of Novartis began research on the target. | LAG-525 | Ieramilimab | LAG3 [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Plamotamab | Plamotamab (XmAb13676) is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3).An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life,stability and ease of manufacture on plamotamab.CD20 is highly expressed on B-cell tumor cells, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) cells.Engagement of CD3 by plamotamab activates T cells for highly potent and targeted killing of CD20-expressing tumor cells. The structural stability and modularity enabled by the XmAb Bispecific Fc domain allowed the tuning of plamotamab’s potency to balance anti-tumor activity with the reduction of immune toxicity that can result from T-cell activation. | XmAb-13676 | Plamotamab | CD3E/MS4A1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa / scFv-h-CH2-CH3 | info@doronscientific.com |
| Vibecotamab | XmAb14045 | Vibecotamab | CD3 epsilon/ IL3RA[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | IgG1-kappa / scFv-h-CH2-CH3 | info@doronscientific.com | |
| Tidutamab | XmAb-18087 | Tidutamab | CD3 epsilon/SSTR2[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric, Humanized | 1mg/ml | IgG1-kappa / scFv-h-CH2-CH3 | info@doronscientific.com | |
| Nimacimab | RYI-018 | Nimacimab | CNR1[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Semorinemab | Semorinemab is anti-Tau antibody that can help clear Tau protein deposits in the brain. | RO-7105705 | Semorinemab | MAPT[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Bedinvetmab | ZTS-00508841 | Bedinvetmab | NGF/NGFB[Canis lupus familiaris] | store at -80°C | 100ug and 1mg | Caninized | 1mg/ml | IgG2-lambda | info@doronscientific.com | |
| Relfovetmab | ZTS-00084768 | Relfovetmab | NGF/NGFB[Felis catus] | store at -80°C | 100ug and 1mg | Felinized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Atoltivimab | Atoltivimab can target Ebola virus and is expected to be used for post-exposure prevention of this deadly virus. | REGN-3470-3471-3479 | Atoltivimab | Zaire Ebola virus[Zaire ebolavirus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Nidanilimab | CAN04 (nidanilimab), a fully humanized monoclonal antibody against the novel antitumor target, IL1RAP, in patients with solid tumor malignancies. | CAN-04, | Nidanilimab | IL1RAP[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Quetmolimab | Antibody drug targeting CX3CL1. | E-6011 | Quetmolimab | CX3CL1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Cinpanemab | BIIB-054 | Cinpanemab | SNCA [Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Disitamab | RC48-0 | Disitamab | ERBB2/EGFR2/CD340[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Envafolimab | Envafolimab (KN035) is the first humanized anti-PD-L1 single domain antibody and new fusion protein of human IgG1 Fc. Compared with the PD-1/PD-L1 antibody that is currently on the market and under development, it has obvious advantages. . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and rapid tumor penetration, thereby improving the compliance of cancer patients with medication and improving the quality of life of patients. It is in line with the future trend of long-term management of cancer as a chronic disease. | KN-035 | Envafolimab | CD274/PD-L1/B7-H1[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric | 1mg/ml | (VH-CH2-CH3)2 | info@doronscientific.com |
| Actinium (225Ac) Lintuzumab Satetraxetan | HuM195 | Actinium (225Ac) Lintuzumab Satetraxetan | CD33[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Amivantamab | JNJ-61186372,JNJ-6372 | Amivantamab | EGFR/ME/RCCP2[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Anetumab Corixetan | BAY 2287409 | Anetumab Corixetan | MSLN | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Astegolimab | AMG-282,MSTT-1041A,RG-6149,RO-7187807 | Astegolimab | IL1RL1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Avdoralimab | IPH-5401,NN-8210,NNC-0215-0384 | Avdoralimab | C5AR1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Avizakimab | BOS161721 | Avizakimab | IL21[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Axatilimab | SNDX-6352,UCB-6352 | Axatilimab | CSF1R/CD115[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Batoclimab | Batoclimab (HBM9161) is fully human antibody targeting neonatal Fc receptor (FcRn). It can accelerate the degradation of autoantibodies in patients with optic neuromyelitis spectrum diseases and other autoimmune diseases. FcRn expression is upregulated by pro-inflammatory cytokines (such as TNF-α) and prolongs the half-life of IgG and serum albumin by reducing lysosomal degradation in endothelial cells and bone marrow-derived cells. Blocking the FcRn-IgG interaction can accelerate the degradation of autoantibodies and mitigate the onset of various pathogenic IgG-mediated autoimmune diseases, including myasthenia gravis, thyroid eye disease, optic neuromyelitis spectrum disease, and immunity Thrombocytopenia. | HL161 | Batoclimab | FCGRT[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Befovacimab | BAY-1093884 | Befovacimab | TFPI [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens；Humanized | 1mg/ml | IgG2-lambda | info@doronscientific.com | |
| Benufutamab | GEN1029 | Benufutamab | TNFRSF10B/TRAILR2/ CD262[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric；Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Cosibelimab | Cosibelimab is a fully-human monoclonal IgG1 antibody that blocks the interaction between PD-L1 and PD-1 and certain receptors called B7.1 by binding to PD-L1. | CK-301 | Cosibelimab | CD274/PD-L1/B7-H1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Dovanvetmab | ZTS-00521505 | Dovanvetmab | IL31[Felis catus] | store at -80°C | 100ug and 1mg | Felinized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Encelimab | TSR-033 | Encelimab | LAG3/CD223[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Epcoritamab | Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody technology.It targets CD20 on the B-cells,a clinically well-validated target that is expressed in a wide variety of B-cell malignancies.Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B cell malignancies. | GEN3013 | Epcoritamab | CD3E;MS4A1/CD20[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens;Chimeric | 1mg/ml | IgG4-kappa-lambda | info@doronscientific.com |
| Fianlimab | The antibody drug against LAG-3 is indicated for malignant tumors. | REGN3767 | Fianlimab | LAG3/CD223[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Gatralimab | GZ-402668 | Gatralimab | CD52[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric;Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Glofitamab | CD20-TCB (2:1),RG-6026 | Glofitamab | CD3E/MS4A1[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa-lambda | info@doronscientific.com | |
| Gremubamab | Gremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults). | MEDI3902 | Gremubamab | PcrV[Bradyrhizobium sp.ANU 289,Gram negative bacteria] | store at -80°C | 100ug and 1mg | Homo sapiens,Humanized | 1mg/ml | VH-CH1-VH-V-KAPPA-CH2-CH3 | info@doronscientific.com |
| Ivuxolimab | PF-04518600 | Ivuxolimab | TNFRSF4/CD134[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com | |
| Lodapolimab | The antibody drug against PDL1. | LY3300054 | Lodapolimab | PDCD1/PD-1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com |
| Manelimab | BCD-135 | Manelimab | CD274/PD-L1/B7-H1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-lambda | info@doronscientific.com | |
| Mavezelimab | MK-4280 | Mavezelimab | LAG3/CD223[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Mirzotamab | ABBV-155 | Mirzotamab | CD276/B7-H3[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Mirzotamab Clezutoclax | ABBV-155 | Mirzotamab Clezutoclax | CD276/B7-H3[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Nurulimab | BCD-145 | Nurulimab | CTLA4[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Odesivimab | REGN-3470-3471-3479,REGN-3470/REGN-3471/REGN-3479 | Odesivimab | Zaire Ebola virus[Zaire ebolavirus] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Odronextamab | The antibody drug against MS4A1, CD20-CD3 bispecific antibody REGN1979 (odronextamab) has shown good results when treating a variety of B-cell NHL patients. | REGN-1979 | Odronextamab | CD3E[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Pacmilimab | CX-072 | Pacmilimab | CD274/PD-L1/B7-H1[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Patritumab Deruxtecan | U3-1287 | Patritumab Deruxtecan | ERBB3 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Petosemtamab | MCLA-158 | Petosemtamab | EGFR/ERBB1/LGR5[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Praluzatamab | CX-2009 | Praluzatamab | ALCAM/CD166[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Praluzatamab Ravtansine | CX-2009 | Praluzatamab Ravtansine | ALCAM/CD166[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Retifanlimab | Retifanlimab (INCMGA-0012) is anti-PD-1 monoclonal antibody. INCMGA0012 is currently in the stage of clinical proof of concept (PoC). At the same time, Incyte is exploring the efficacy of INCMGA0012 monotherapy in high-satellite unstable endometrial cancer and Merkel cell carcinoma. | INCMGA-00012,MGA-012 | Retifanlimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Chimeric,Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Sasanlimab | Antibody drug against PD1. | PF-06801591 | Sasanlimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Serplulimab | HLX10 | Serplulimab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com | |
| Sonelokimab | M-1095,MSB-0010841 | Sonelokimab | ALB,IL17A[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | VH-VH’-VH | info@doronscientific.com | |
| Tafolecimab | GPRC5D / CD3 bispecific antibody is used to treat multiple myeloma. The bispecific antibody is commonly known as tafolecimab. It is constructed using the Duobody technology authorized by Genmab. The heavy chain of anti-CD3 antibody introduced F405L and R409K to construct the double antibody. S228P, F234A, and L235A mutations were simultaneously introduced into the IgG4 constant region. | IBI-306 | Tafolecimab | PCSK9[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | IgG2-kappa | info@doronscientific.com |
| Tilvestamab | Ab-2,BGB-149 | Tilvestamab | PCSK9[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Tinurilimab | BAY-1834942 | Tinurilimab | CEACAM6[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Vibostolimab | MK-7684 | Vibostolimab | TIGIT/VSIG9/VSTM3[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Zagotenemab | Zagotenemab is an antibody drug that targets TAU protein, and has started Phase II clinical trial in April 2018. | LY-3303560 | Zagotenemab | MAPT[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG4-kappa | info@doronscientific.com |
| Zelminemab | AMG-301 | Zelminemab | ADCYAP1R1[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com | |
| Ziltivekimab | Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). | COR-001 | Ziltivekimab | IL6 [Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens;Humanized | 1mg/ml | IgG1-kappa | info@doronscientific.com |
| Tocilizumab | Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody,prevents binding of IL-6 to the IL-6R,thereby inhibiting both classic and trans-signaling.Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. | Atlizumab,MRA/R-1569/RHPM-1/RO-4877533 | Tocilizumab | IL-6R | store at -80°C | 100ug and 1mg | 1mg/ml | IgG1 | info@doronscientific.com | |
| Basilixumab | Basiliximab;CHI-621/SDZ-CHI-621 | Basilixumab | IL-2 receptor | store at -80°C | 100ug and 1mg | 1mg/ml | IgG1k | info@doronscientific.com | ||
| Tavolimab | MEDI0562 | Tavolimab | TNF- SF4 receptor I[Homo sapiens] | store at -80°C | 100ug and 1mg | Homo sapiens | 1mg/ml | TBP-1:tumor necrosis factor (TNF) binding protein variant 1 | info@doronscientific.com | |
| Veltuzumab | Veltuzumab is a monoclonal antibody which,as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin’s lymphoma. | hA20/IMMU-106 | Veltuzumab | CD20 receptors[Homo sapiens] | store at -80°C | 100ug and 1mg | 1mg/ml | info@doronscientific.com | ||
| Teplizumab | This is anti-CD3 monoclonal antibody used to prevent or delay the development of clinical type 1 diabetes (T1D) in high-risk groups. High-risk groups refer to the presence of 2 or more T1D-related autoantibodies in the body. | MGA-031/MGA031;PRV-031 | Teplizumab | CD3 | store at -80°C | 100ug and 1mg | 1mg/ml | info@doronscientific.com | ||
| Pembrolizumab | Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy. | MK-3475 | Pembrolizumab | PDCD1/PD1/CD279[Homo sapiens] | store at -80°C | 100ug and 1mg | Humanized | 1mg/ml | IgG1 | info@doronscientific.com |
Reviews
There are no reviews yet.